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These STIKO vaccination recommendations were endorsed during the 82nd and 84th 
STIKO meetings and are considered enacted upon their publication on 29 August 2016. 
This 2016 version replaces the previous STIKO vaccination recommendations pub-lished 
in August 2015 in Epidemiologisches Bulletin (Epid. Bull.) 34/2015 of the Robert Koch 
Institute (RKI). The scientific rationale for the modified STIKO recommendations will be 
available in Epid. Bull. 35/2016, 36/2016, and 37/2016 on the RKI website.
National immunisation schedule available in 20 languages: www.stiko.de/en. 
1. Preliminary remarks
Vaccinations are among the most effective and significant preventive medical 
measures. Modern vaccines are well tolerated, and irreversible serious  adverse 
events (SAE) are observed only in very rare cases. The immediate goal of 
vaccination is to protect an individual from a specific disease. Given a high 
level of acceptance within the population and a consistent vaccination policy 
supported by all stakeholders, high vaccination coverage rates can be attained. 
Consequently, it is possible to achieve regional elimination of single pathogens, 
and eventually to eradicate them worldwide. Elimination of measles, rubella, 
and poliomyelitis are declared and achievable goals of national and international 
health policy.
Compulsory vaccination does not exist in Germany. Vaccinations and other 
means of specific prophylaxis are “publicly recommended” by the health 
authorities of the federal states on the basis of the STIKO recommendations 
according to § 20 (3) of the Protection Against Infection Act [Infektionsschutz-
gesetz (IfSG)]. Compensation of vaccine-induced injury caused by “publicly 
recommended” vaccinations is assured by the federal states.
An important task for a physician is to ensure adequate immunisation for all 
persons under his care. This means starting primary immunisation early in 
infants and toddlers, administering these vaccines without delays, and 
completing vaccination schedules in a timely manner. Following primary immu-
nisation, using regular booster vaccinations when applicable, the physician must 
ensure that the necessary protection is maintained throughout the life of the 
individual, and that immunisation against further infectious diseases is initiated 
when indicated. Therefore, every visit to the physician should be used to check 
the vaccination records of children, adolescents, and adults, and to complete 
immunisation schedules when necessary.
Overview of new or updated recommendations 
in 2016:
 ▶ Routine pneumococcal vaccination for all 
adults aged 60 years and older (see Immu-
nisation Schedule, p. 303, table 2, p. 308 
and notes, p. 313)
 ▶ Risk-based pneumococcal vaccination for 
children and adults (see table 2, p. 308 and 
notes, p. 313)
 ▶ Guidance on reducing pain and distress at 
the time of vaccination, p. 318
Disclaimer
This document is a translation of the original Recommendations of the Standing Committee on 
Vaccination (STIKO) at the Robert Koch Institute (www.rki.de/stiko-empfehlungen) on behalf 
of the Robert Koch Institute as of 8/2016. The German text is authoritative, and no liability is 
assumed for any translation errors or for the translation’s correctness in case of subsequent 
revisions to the German original.
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The routine immunisation schedule for infants, children, 
adolescents and adults (Table 1) includes vaccinations 
against tetanus (T), diphtheria (D/d), pertussis (aP/ap), 
Haemophilus influenzae type b (Hib), poliomyelitis (IPV), 
hepatitis B (HB), pneumococci, rotavirus (RV), menin-
gococcal C, measles, mumps, rubella (MMR), varicella, 
Human Papillomaviruses (HPV) and influenza. 
The recommended time of vaccination is indicated in 
weeks, months, and years. For example, “vaccination at 
the age of 5 to 6 years” means that vaccination should 
take place between the day of the child’s 5th birthday and 
the day before the 7th birthday. Vaccination should take 
place at the earliest recommended time. To keep the num-
ber of injections as low as possible, combination vaccines 
should preferably be used if available and as long as they 
do not conflict with current STIKO recommendations. It 
is recommended to check and, when necessary, update the 
vaccination status at every age. Missing vaccinations should 
immediately be administered in accordance with the re-
commendations for the respective age. 
Regarding minimum intervals between two vaccinations 
and the possibility of co-administering vaccines, the Sum-
mary of Product Characteristics (“physician insert”) for 
the respective vaccine product should be consulted. It 
is of particular importance for long-term vaccine-induced 
protection that, for primary immunisation, the recommen-
ded minimum interval between the second-to-last and last 
vaccination is not shortened. 
The specified vaccination intervals take into account the mi-
nimum intervals between vaccinations necessary to induce 
protection. 
Vaccination records should be checked and immunisations 
provided especially during the healthy-child visits that 
infants and children routinely undergo, the school-
entry health examination, health checks that take place 
throughout schooling, adolescent health checks, examina-
tions in accordance with the Young Persons Employment 
Act [Jugendarbeitsschutzgesetz], and preventive medical 
examinations for adults. All persons with chronic diseases 
should receive the standard vaccinations recommended in 
the immunisation schedule as long as there are no specific 
contraindications.
Because of the particular increased risk of acquiring infec-
tious diseases or developing a severe course of a disease in 
early childhood, the goal must be to administer recommen-
ded vaccinations for infants as early as possible and to com-
plete primary immunisations by the recommended ages 
of 14 months (for MMR and Varicella by 23 months) at the 
latest. Experience shows that vaccinations started later than 
recommended are often not continued within the correct 
timeframe. Until vaccination gaps have been detected and 
closed, for instance at the school-entry health examination, 
inadequately vaccinated children have insufficient vaccina-
tion protection. Age-appropriate full vaccination protection 
must be ensured before entry to a community facility, at the 
latest prior to starting school. In adolescents, missed vacci-
nations must be reinstated by the age of 18 at the latest (that 
is, by the day before their 18th birthday).
Please note that catch-up vaccination against Hib should be 
administered only until the age of 5 years and vaccination 
against pneumococci only until the age of 2 years. Rotavirus 
vaccination must be completed by the ages of either 24 or 
32 weeks depending of the vaccine product used.
2. Immunisation schedule (routine vaccinations)
In addition to administering the vaccine, the vaccination services provided by the physician include:
 ▶ Providing information on the disease to be prevented and the benefits of vaccination;
 ▶ Providing information on possible adverse events following immunisation;
 ▶ Taking the patient’s medical and vaccination history, including possible existing contraindications;
 ▶ Determining current health status in order to exclude acute illnesses;
 ▶ Giving behavioural recommendations subsequent to the vaccination;
 ▶ Giving information on the commencement and duration of the protective effect;
 ▶ Giving advice on booster vaccinations; and
 ▶ Documenting the vaccination in the patient’s vaccination record or issuing a vaccination certificate.
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3.  Adult vaccinations: standard, indicated, and booster vaccinations, and vaccinations for  
 increased occupational risk or travel
3.1 Overview
To comply with the immunisation schedule for infants, 
children, adolescents and adults (see Table 1, p. 303) vacci-
nation status should be checked regularly and brought up to 
date where necessary; each medical consultation should be 
utilised for this.
Beside standard vaccinations (S), other vaccinations may 
be indicated in a particular epidemiological situation or 
where there is a particular hazard to children, adolescents, 
and adults; these are referred to as indicated vaccinations (I). 
Vaccinations due to occupational risks (O) and travel vacci-
nations (T) are particular cases of indicated vaccinations and 
are therefore also listed. Travel vaccinations may be required 
to comply with international health regulations (including 
yellow fever vaccination) or may be recommended for indivi-
dual protection while travelling.
It is the physician’s responsibility to recommend the type 
and chronological order of vaccinations in each individual 
case, considering the indications and, where applicable, exis-
ting contraindications.
If the individual indication for vaccination is not covered by 
a licensure valid for Germany or by the Summary of Product 
Characteristics of the corresponding vaccine, it comprises 
an off-label use. In case of injury, off-label use has conse-
quences for liability and compensation and places particu-
lar obligations on the physician administering the vaccine 
regarding documentation and the provision of information. 
Benefit claims for a recognised injury due to vaccination 
pursuant to § 60 Protection Against Infection Act (Infekti-
onsschutzgesetz [IfSG]) are granted only for vaccinations 
officially recommended by state health authorities.
The vaccinations mentioned in Table 2 differ both in terms 
of their epidemiological significance and in terms of the 
coverage of their cost (see notes on the cost coverage of 
protective vaccines, p. 320); they are divided into the 
following categories:
S Standard vaccinations for universal application (see also 
Table 1, p. 303, immunisation schedule)
B Booster vaccinations
I Indicated vaccinations for risk groups with a personally 
(rather than professionally) increased risk of exposure, ill-
ness, or complications, as well as to protect third parties
O Vaccinations due to an increased occupational/ 
professional risk, for example after risk assessment in 
accordance with the Occupational Safety and Health Act 
[Arbeitsschutzgesetz], the Biological Agents Ordinance 
[Biostoffverordnung], the Regulation Concerning Occu-
pational Healthcare [Verordnung zur arbeitsmedizini-
schen Vorsorge (ArbMedVV)], and the ‘G 42’ screening, 
as well as for hygiene reasons
T Travel vaccinations
In addition to vaccinations recommended by STIKO, 
further vaccines might be indicated based on the exis-
ting licensure of a vaccine. These specific indications 
are not discussed further below, but they can be useful 
for the protection of an individual, depending on his or 
her individual health situation. It is the physician’s 
responsibility to inform patients of these additional 
protective options. The lack of a STIKO recommen- 
dation should not prevent a physician from carrying 
out further vaccinations when justified.
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Vaccination Cate- Indication Notes on use (Note package leaflet/Summary of  
against gory   Product Characteristics)
Cholera Periods of residence in infected areas, especially with inadequate 
hygiene conditions in current outbreaks, e. g., in refugee camps 
or during natural disasters.
According to the Summary of Product Characteristics.T
Diphtheria S/B All persons with absent or incomplete primary immunisation, 
or if either the last vaccination for the basic immunisation or 
the last booster vaccination occurred greater than 10 years pre-
viously.
Adults should receive the next due diphtheria vaccina-
tion as a one-time Tdap combination vaccination, if 
indicated as a Tdap-IPV combination vaccination.
If diphtheria vaccination is indicated and adequate vac-
cination protection against tetanus and pertussis is in 
place, a monovalent diphtheria vaccine should be given.
Unvaccinated persons or those with no vaccination 
record should receive 2 vaccinations at intervals of 
4 – 8 weeks and a 3rd vaccination 6 – 12 months after 
the 2nd vaccination. Travel to an epidemic area should 
not be undertaken prior to receipt before of 2 doses.





I Persons with anatomical or functional asplenia. One-time vaccination. Whether revaccination is useful 







►  Persons whose sexual behaviour entails a high risk of infection.
► Persons frequently receiving blood components, e. g., haemo- 
 philiacs, or persons with liver diseases/diseases involving the 
 liver.
►  Residents of psychiatric institutions or comparable welfare 
facilities for people with behavioural disorders or cerebral 
damage. 
Primary immunisation and booster vaccination 
according to the Summary of Product Characteristics.
Serological screening for anti-HAV is required only 
for persons who have lived for prolonged periods in 
endemic regions or grew up in families from endemic 
regions or were born before 1950.
►  Health care workers (including kitchen, laboratory, technical 
and cleaning services, ambulance services, psychiatric and 
welfare institutions, sheltered employment facilities, and 
asylum seekers’ shelters), including trainees and students: 
at risk of contact to potentially infectious stools. 
►  Sewer system and wastewater workers in contact with sewage.
►  Employment (including kitchen and cleaning) in children’s day 
care centres, children’s homes, and the like. 






1. Persons who are at risk of severe hepatitis B owing to an exis-
ting or expected immunodeficiency or immunosuppression, or 
owing to other pre-existing diseases, for example: HIV-positive 
individuals, hepatitis C-positive individuals, and patients on 
haemodialysis. *
2. Persons who are at increased risk of non-occupational expo-
sure, for example: persons in contact with HBsAG carriers 
in the family or flat share, persons at high risk to acquire he-
patitis B through sexual contact, injection drug users, prison 
inmates, and if applicable psychiatric inpatients.*
3. Persons who are at increased risk of occupational exposure, 
for example: Health care personnel at risk of exposure (inclu-
ding trainees, laboratory personnel, and cleaning personnel), 
first aid providers, police officers, and personnel at facilities 
where an increased prevalence of hepatitis B-virus (HBV)- 
infected persons is likely to be present (for example, correctio-
nal facilities, shelters for asylum seekers, and homes for the 
handicapped).*,**
4. Travel-related indication: an individual risk assessment is 
required. 
For indication groups 1 – 4, the following applies:
Routine serological testing to rule out an existing HBV in-
fection prior to hepatitis B vaccination is not necessary. It 
is riskless to vaccinate persons already infected with HBV 
against hepatitis B; however, the vaccination is not effecti-
ve. Serological testing can be reasonable in specific situa-
tions (for example, for financial reasons, to avoid unneces-
sary vaccinations, or in case of high anamnestic risk of ex-
posure, including if a sexual partner is HBsAG positive).**
To monitor vaccination success, anti-HBs level should be 
determined 4 – 8 weeks after the 3rd vaccine dose (success-
ful vaccination: anti-HBs ≥ 100 IU/l).***
For “low-responders” (anti-HBs 10 – 99 IU/l) an immedia-
te additional vaccine dose is recommended in connection 
with repeated anti-HBs monitoring 4 – 8 weeks after vacci-
nation. If anti-HBs is still < 100 IU/l, up to 2 additional 
doses are recommended with subsequent anti-HBs moni-
toring 4 – 8 weeks after each vaccination. There is contro-
versy over reasonable proceedings if the anti-HBs level re-
mains < 100 IU/l after the administration of in total 6 vac-
cine doses; for further explanation see Epid. Bull. 36/2013.3 
(www.rki.de > Infektionsschutz > Epidemiologisches Bulle-
tin > issue 36/2013).
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Vaccination Cate- Indication Notes on use (Note package leaflet/Summary of  
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Influenza Adults ≥ 60 years of age.
All pregnant women from the second trimester, or from the first 
trimester in case of an increased health risk resulting from an 
underlying disease.
Children, adolescents and adults with an increased health risk 
resulting from an underlying disease, such as:
▶  Chronic diseases of the respiratory tract (including asthma and 
COPD),
▶  Chronic cardiovascular, liver and kidney diseases,
▶  Diabetes and other metabolic diseases,
▶ Chronic neurological diseases, e. g., multiple sclerosis with 
 relapses triggered by infections,
▶  Persons with congenital or acquired immunodeficiencies with 
residual T- and/or B-cell function,
▶  HIV infection.
Residents of retirement or nursing homes.
Persons who might act as a potential source of infection for 
at-risk patients by living in the same household or by taken care 
of them. At risk are considered persons with underlying diseases, 
who are more likely to experience a reduced response to influen-
za vaccines, e.g. patients with dialysis-dependent renal disease or 
persons with congenital or acquired immunodeficiency or immu-
nosuppression. 
Persons at increased risk, e. g., medical personnel, persons in 
establishments dealing extensively with the public, as well as 
persons who may act as a possible source of infection by caring 
for individuals at particular risk.
Persons at increased risk by direct contact with poultry and wild 
birds.*
Yearly vaccination in autumn with a vaccine containing 
the current antigen combination recommended by WHO.
Vaccination with a vaccine containing the current anti-
gen combination recommended by the WHO.
Annual vaccination in autumn with a vaccine containing 
the current antigen combination recommended by the 
WHO. 
Children and adolescents aged 2 to 17 years can be 
vaccinated with an inactivated influenza vaccine or a live 
attenuated influenza vaccine (LAIV) if no contraindica-
tions exist (see Summary of Product Characteristics). 
LAIV should be preferred in children aged 2 to 6 years.
Yearly vaccination in autumn with a vaccine containing 
the current antigen combination recommended by WHO. 
* Vaccination with the current seasonal human 
influenza vaccine does not offer direct protection 
against infection with the avian influenza virus. It can, 
however, prevent double-infection with the currently 
circulating influenza viruses (see also: TRBA 608 of the 
ABAS at www.baua.de > Topics from A – Z > Biological 




Please see p. 311
(Table 2 continued)
For the coming influenza season 
2016/2017, STIKO has suspended the 
recommendation to preferentially vacci-
nate children aged 2 to 6 years with LAIV 
(s. STIKO Advisory Statement at www.
rki.de > Infektionsschutz > Epidemiolo-




*  This list of groups of persons provides examples and is not intended to be 
 a definitive list of indicated groups. In any case, an individual risk assess- 
 ment is required (see Epid. Bull. 36/2013).2
**  In the field of occupational health services, the recommendations of the 
 ArbMedVV should be attended as well.
***  For persons belonging to indication group 4 (travel vaccination) it is 
necessary to evaluate whether, in view of the real risk of exposure and 
the individual risk of non-responding, serological monitoring is necessary.
In the case of “non-responders” (anti-HBs < 10 IU/l) it is 
recommended to test for HBsAG and anti-HBc to exclu-
de an existing chronic HBV infection. If both parameters 
are negative, proceed as described for “low-responders,” 
above.
After successful primary vaccination, defined as anti-
HBs ≥ 100 IU/l, routine booster immunisations are 
usually not necessary. The exceptions are patients with 
humoral immune deficiency (annual anti-HBs monito-
ring and a booster dose when anti-HBs < 100 UI/l), 
and if applicable, persons who are at particularly high 
individual exposure risk (anti-HBs monitoring after 10 
years and a booster dose if anti-HBs < 100 UI/l).
An additional vaccine dose followed by serological moni-
toring described above should be administered to persons 
vaccinated against hepatitis B during infancy with a newly 
arisen risk for hepatitis B infection (see indications 1 – 4) 
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For travellers aged > 60 years and the groups of persons named 
under I (indicated vaccination) whose influenza vaccination 
status is not up to date, vaccination is generally advisable. For 
other travellers an influenza vaccination may be advisable after a 
risk assessment depending on exposure and vaccine availability.
Vaccination with a vaccine containing the current 
antigen combination recommended by the WHO.
If a full-scale epidemic based on experiences in other countries is 
impending or is to be expected following a manifest antigenic drift 
or antigenic shift and the vaccine contains the new variant.
According to the recommendations of the health 
authorities.
Measles S Those ≥ 18 years and born after 1970 with unclear vaccination 
status, who have not been vaccinated, or who received only one 
vaccination during childhood.
Vaccination with 2 doses of a MMR/V*-vaccine
Provided that the first vaccination has been given at 
the age of 9 to 10 months, the 2nd MMR/V vaccination 
should be given at the beginning of the 2nd year of life. 
One-time vaccination, preferably with a MMR vaccine.
With forthcoming admission or visit of a community 
facility (e. g. Kindergarten): 




One-time vaccination with MMR(V)**vaccine
If necessary complement vaccinations according to 
the recommendations applying for the respective age 
group. Provided that the first vaccination has been 
given at the age of 9 to 10 months, the 2nd MMR/V* 
vaccination should be given at the beginning of the 2nd 
year of life.
With first vaccination at the age of 6 to 8 months a 2nd 
and 3rd MMR/V*vaccination should be administered at 
the age of 11 to 14 and 15 to 23 months 
* MMR/V = MMRV or MMR in co-administration with VZV vaccine
** MMR(V) = MMR with or without co-administration of VZV 
 vaccine
During an outbreak:
 ▶ Those born after 1970 from the age of 9 months with unclear 
vaccination status, who are unvaccinated, or who received 
only one vaccination during childhood.
 ▶ 6 to 8 month-old infants exceptionally after individual risk 
benefit consideration (Off-label-use).
Those born after 1970 with unclear vaccination status, who 
have not been vaccinated, or who received only one vaccination 
during childhood and who are working in health care or com-
munity facilities, or who care for immunodeficient or immuno-
suppressed individuals.
O One-time vaccination with a MMR vaccine.
Meningococcal 
infections 
I Those whose health is at risk: Persons with congenital or acqui-
red immunodeficiencies with residual T- and/or B-cell function, 
especially:
 ▶ complement/properdin deficiencies, 
 ▶ Treatment with Eculizumab (monoclonalal antibody against 
terminal complement component C5),
 ▶ hypogammaglobulinaemia, 
 ▶ asplenia.
Vaccination against serogroups A, C, W, Y and/or B, if 
licensed for the respective age group.
For further details regarding implementation of meningo-
coccal vaccination see p. 312.
At-risk laboratory personnel (in the case of work involving a risk of 
N. meningitidis aerosols).
Vaccination with quadrivalent ACWY-conjugate vaccine 
and a Men-B-vaccine. 
O
I During outbreaks or regional clusters upon recommendation by 
the local health authorities (see p. 325).
In accordance with the recommendations of the health 
authorities.
Those travelling to countries with epidemic/hyperendemic occurren-
ces, especially in close contact with the indigenous population (e. g., 
development aid workers, disaster relief workers, medical personnel, 
long-term stays); this also applies to stays in regions with disease 
outbreaks and vaccination recommendation for the indigenous 
population (note WHO and country-specific information).
Vaccination with a quadrivalent conjugate vaccine, if 
licensed for the respective age group (see p. 312).
T
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Mumps O Individuals born after 1970 with unclear vaccination status, who 
have not been vaccinated, or who received only one vaccination 
in childhood and who are working in health care with direct pati-
ent contact, in community facilities, or in educational establish-
ments for young adults. 18
One-time vaccination with MMR vaccine.
(Table 2 continued)
▶ persons in close household contact (parents and siblings) 
and caregivers (e. g., day nannies, babysitters, and where 
applicable grandparents), if possible 4 weeks before the birth 
of the child.
If a mother was not vaccinated before conception, she should 
preferably be vaccinated during the first days following the birth 
of her child.
Before a pilgrimage (Hajj, Umrah). Vaccination with a quadrivalent conjugate vaccine (sero-
groups A, C, W, Y), if licensed for the respective age 
group (see p. 313). Take note of entry regulations.
Students before long-term stays in countries with recommended 
standard vaccination of adolescents or selective vaccination of 
students.
In accordance with the recommendations of the destina-
tion countries.
If in the last 10 years there has been no pertussis vaccinati-
on, personnel in health care as well as in community facilities 





If in the last 10 years there has been no pertussis vaccination, the 
following groups should receive one dose of pertussis vaccine:
▶  women of childbearing age,
Adults should receive the next due Td vaccine as a one-time Tdap 
combination vaccine.
Vaccination with a Tdap combination vaccine, if indi-
cated as a Tdap-IPV combination vaccine. (For available 








Children, adolescents and adults at increased health risk as a 
result of an underlying disease:
1. Congenital or acquired immune-deficiencies or immuno- 
 suppression, such as:
 ▶ T-cell deficiency or defective T-cell function,
 ▶ B-cell or antibody deficiency (e. g., hypogammaglobulinaemia),
 ▶ Deficiency or dysfunction of myeloid cells (e. g., neutropenia, 
chronic granulomatosis, leukocyte adhesion deficiencies, 
signal transduction defects),
 ▶ Complement and properdin deficiencies,
 ▶ Functional hyposplenism (e. g., sickle cell anaemia),  
splenectomy*, or anatomical asplenia,
 ▶ Neoplastic diseases,
 ▶ HIV infection,
 ▶ After bone marrow transplantation,
 ▶ Immunosuppressive therapy* (e. g., due to organ  
transplantation or autoimmune disease),
 ▶ Immunodeficiency in the context of chronic kidney failure, 
nephrotic syndrome or chronic liver insufficiency.
2.  Other chronic diseases, such as:
 ▶ Chronic diseases of the cardiovascular system or of the res-
piratory tract (e. g., asthma, emphysema, or COPD), liver or 
kidney 
 ▶ Metabolic diseases, e. g. diabetes mellitus treated with oral 
medication or insulin
 ▶ Neurological diseases, e. g., cerebral palsy or seizure 
disorders
1. Sequential vaccination with 13-valent conjugate vacci-
ne (PCV13), followed by PPSV23 after 6 – 12 months. 
PPSV23 should only be given to individuals aged 
2 years and older.** 
Adults > 60 years of age. Vaccination with 23-valent polysaccharide vaccine 
(PPSV23). If applicable, repeat vaccinations with 
PPSV23 at intervals of at least 6 years according to indi-
vidual indication, see p. 313. 
I
2. Individuals older than 16 receive a vaccination with 
PPSV23; those aged 2 – 15 receive a sequential vaccinati-
on with PCV13, followed by PPSV23 after 6 – 12 months.** 
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3.  Anatomical and foreign-material associated risks for  
  pneumococcal meningitis, such as:
 ▶ Cerebral spine fluid fistula
 ▶ Cochlea implant *
* vaccination preferably before intervention
(Table 2 continued)
O Professional activity such as welding or separating metals 
leading to exposure to metal smoke, including metal-oxidic 
welding smoke.
Vaccination with PPSV23 and repeat vaccination with 
PPSV23 at minimum intervals of 6 years as long as 
exposure continues. 
Poliomyelitis S/B All persons with no or incomplete primary immunisation.
All persons without a one-time booster vaccination.
Adults are considered fully immunised if they have 
received the complete primary immunisation in 
infancy and childhood and at least one booster vac-
cination in adolescence or later, or if they have recei-
ved primary immunisation as adults in accordance 
with the Summary of Product Characteristics and 
have received a booster vaccination.
3. Sequential vaccination with PCV13 followed by PPSV23 
after 6 – 12 months. PPSV23 should only be given to indi-
viduals aged 2 years and older. **
**As these vaccines provide only temporary protection, 
the vaccination with PPSV23 should be repeated in all 
three risk groups at intervals of at least 6 years. 
For information on practical implementation, see chap-







Persons exposed to ticks in TBE risk areas.
Persons at risk of TBE through their profession (exposed 
laboratory personnel as well as those in risk areas, including 
forest workers and those exposed during farming).
Tick exposure in TBE risk areas outside Germany.
Primary immunisation and booster vaccinations with a 
vaccine authorised for adults and/or children according 
to the Summary of Product Characteristics.
According to the recommendations of the health au-
thorities, information on TBE risk areas must be noted; 
these are published in Epid. Bull. 18/2016 (www.rki.de 
> Infektionsschutz > Epidemiologisches Bulletin > issue 
18/2016. 
O  ▶ Personnel of the above-mentioned institutions, 
 ▶ Medical personnel who may have close contact with cases,
 ▶ Personnel in laboratories with a poliomyelitis risk.
Vaccination or booster vaccination with IPV, if primary 
immunisation is incomplete or if the last of the primary 
or the last booster vaccination dates back longer than 
10 years.
A vaccination is indicated for the following groups of persons:
▶  Those travelling in regions with risk of infection (the current 
epidemic situation must be taken into account, especially the 
WHO reports),
▶  Immigrants, refugees and asylum seekers who live in commu-
nal accommodation, entering from regions at risk of polio; 
see p. 321.
Vaccination or booster vaccination with IPV, if primary 
immunisation is incomplete or not fully documented or 
the last vaccination dates back longer than 10 years.
Persons with no primary immunisation record should 
receive at least 2 doses of IPV before starting their 
travels.
I
Missing primary immunisation vaccinations are reinsta-
ted with IPV in accordance with the Summary of Product 
Characteristics.
Beyond the above, a routine booster vaccination is not 
recommended for adults. 
Rubella I
O
Women of childbearing age that are non-immunised or with an 
unclear vaccination status.30
Women of childbearing age vaccinated once.30
Non-vaccinated persons or persons with an unclear vaccination 
status in paediatrics, obstetrics and pregnancy care institutions 
as well as in community facilities.
Two vaccinations with MMR vaccine.
One vaccination with MMR vaccine.
One vaccination with MMR vaccine. 
Rabies O
T
 ▶ Veterinarians, hunters, forest workers and other persons who 
handle animals in areas where there is a new occurrence of 
rabies among wild animals,
 ▶ Persons with professional or other close contact with bats,
 ▶ Laboratory personnel at risk of exposure to rabies viruses.
Those travelling in high risk rabies regions (e. g., from stray 
dogs).
Dosage schedule according to the Summary of Product 
Characteristics.
Persons with a continued exposure risk should regular-
ly receive a booster vaccination according to the Sum-
mary of Product Characteristics.
Laboratory personnel working with the rabies virus 
should be examined every 6 months for neutrali-
sing antibodies. A booster vaccination is indicated at 
< 0.5 IU/ml serum.
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Tuberculosis Vaccination with a BCG vaccine is not recommended.
Typhus T When travelling in endemic regions. According to the Summary of Product Characteristics. 
Varicella I
O
 ▶ Seronegative women who wish to conceive,
 ▶ Seronegative patients prior to planned immunosuppressive 
therapy or organ transplantation,
 ▶ Susceptible patients with severe neurodermatitis,
 ▶ Susceptible persons in close contact with the two previously 
mentioned groups.
Seronegative personnel in health care, especially in the fields of 
paediatrics, oncology, obstetrics and gynaecology, intensive care 
medicine, those involved in the care of immunodeficient 
persons, and new workers in community facilities for preschool-
age children.
According to the Summary of Product Characteristics.
For information on the vaccination of seronegative 
patients receiving immunosuppressive therapy, please 
refer to Epid. Bull. 39/2005 (www.rki.de > Infektions-
schutz > Epidemiologisches Bulletin > issue 39/2005). 
“Susceptible persons” are defined as individuals with 
no vaccination and no history of varicella or no specific 
antibodies detected upon serological testing.
Tetanus S/B All persons with no or incomplete primary immunisation, if the 
last primary immunisation vaccination or the last booster vacci-
nation dates back longer than 10 years. 
Adults should receive the next due tetanus vaccination 
as a one-time Tdap combination vaccination, if indicated 
as a Tdap-IPV combination vaccination.
Incomplete primary immunisation should be completed, 
booster vaccination should occur at 10-year intervals.
(Table 2 continued)
T  ▶ Before staying in known endemic regions in Africa and Latin 
America; please consult publications of the World Health Orga-
nization (WHO) with information on yellow fever endemic areas 
or
 ▶ according to the vaccination requirements of the destination 
or transit countries.*
One-time vaccination in yellow fever immunisation 
facilities approved by health authorities.
*Since the implementation of the current changes in the Internatio-
nal Health Regulations (IHR), which state that a single dose of yellow 
fever vaccine is sufficient to confer life-long protective immunity and 
a booster dose every 10 years is no longer necessary, will take until 
July 2016, information on countries requiring yellow fever vaccinati-
on for entry (eg WHO: www.who.int/entity/ith/2016-ith-county-list.
pdf?ua=1//; www.who.int/entity/ith/2016-ith-annex1.pdf?ua=1) should 
be considered until then (Web link contains a list of countries with 
the yellow fever vaccine requirements and the further need of a yellow 
fever booster dose).
Note seasonality: April – November
Risk areas in Germany are currently in particular:
▶ Baden-Wurttemberg 
▶  Bavaria (except for a few districts in Swabia and  
western Upper Bavaria) 
▶ Hesse (district of Odenwald, district of Bergstraße, 
district of Darmstadt-Dieburg, city district of Darm-
stadt, district of Groß-Gerau, district of Offenbach, 
city district of Offenbach, district of Main-Kinzig-
Kreis, district of Marburg-Biedenkopf)
▶  Rhineland-Palatinate (district of Birkenfeld)
▶  Saarland (district of Saar-Pfalz)
▶ Saxony (district of Vogtlandkreis)
▶  Thuringia (city district of Jena, city district of Gera, 
district of Saale-Holzland-Kreis, district of Saale-Orla-
Kreis, district of Saalfeld-Rudolstadt, district of Hild-







O When working with contact to Yellow Fever Virus (e. g. in research 
institutions or research laboratories).
One-time vaccination in yellow fever immunisation 
facilities approved by health authorities.
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Diphtheria
From the age of 5 or 6 years, a vaccine with reduced 
diphtheria toxoid content (d) is used for booster vaccination 
and for primary immunisation, generally combined with teta-
nus toxoid and pertussis antigen or other indicated antigens.
Haemophilus influenzae type b (Hib)
From 5 years of age, Hib vaccination is indicated only in 
exceptional cases (see Table 2, p. 305), for example functio-
nal or anatomical asplenia. 
Hepatitis B (HB) 
Pre- and post-vaccination serological testing is not ne-
cessary to monitor the success of primary immunisation 
in childhood and adolescence. Revaccination 10 years fol-
lowing vaccina-tion of infants and toddlers is currently 
not generally recommended for children and adolescents. 
Individuals who have been vaccinated against hepatitis B 
during childhood should be revaccinated against hepatitis 
B if a new risk for hepatitis B has evolved (for example, new 
employment in health care). A serological test should be 
conducted 4 – 8 weeks after vaccination according to re-
commendations in Table 2 (see p. 305) as well as Epid. Bull. 
31/20074 and 36/20133 (www.rki.de > Infektionsschutz > 
Epidemiologisches Bulletin > issues 31/2007, 36/2013). 
Post-exposure Hepatitis B prophylaxis in newborns of HBsAg 
positive mothers or of mothers of unknown HBsAg status 
According to the maternity guidelines, all pregnant women 
should have their serum analysed for HBsAg after the 32nd 
week of pregnancy and as close as possible to the due date. 
If the result is positive, immunisation of the newborn against 
hepatitis B must begin immediately postpartum, that is, 
within 12 hours. The first dose of HB vaccine and HB immu-
noglobulin are thereby simultaneously administered. Primary 
HB immunisation thus started should be completed with a 2nd 
vaccination 1 month after the 1st vaccination, and with a 3rd vac-
cination 5 months at the earliest after the 2nd vaccination.
In newborns including premature babies of mothers 
whose HBsAg status is not known and in whom serological 
testing is not possible before or immediately after delivery, 
primary immunisation with the HB vaccine should also be 
started immediately postpartum regardless of birth weight. 
If the mother is later determined to be HBsAg positive, 
passive immunisation subsequently can be performed in 
the newborn child within 7 days after birth.
Serological testing is required after the completion of 
primary immunisation in the newborn child of an HBsAg 
positive mother: 4 – 8 weeks after the 3rd vaccination dose, 
HBsAg, anti-HBs, and anti-HBc are to be checked. 
Because a lower birth weight can cause a reduced antibo-
dy response, in infants of less than 1,000 gr a serological test 
(anti-HBs) should be conducted 4 weeks after the 2nd vacci-
nation. If the anti-HBs level is ≥ 100 IE/l, the 3rd vaccination 
is given 5 months after the 2nd vaccination. If the anti-HBs 
level is < 100 IE/l, the 3rd vaccination should be administe-
red immediately. Another anti-HBs serological test should be 
conducted 4 weeks later in those infants. If levels are ≥ 100 
IE/l, a 4th vaccination should be given 9 months after the last 
immunisation. If no immunity exists after the 3rd vaccination, 
the 4th dose is to be administered immediately. Vaccination 
success is checked by serological testing (see above). Further 
measures (including possible 5th and 6th vaccinations) need 
to be decided on an individual basis (see Epid. Bull. 10/2000 
and 8/2001, www.rki.de > Infektionsschutz > Epidemiologi-
sches Bulletin > issues 10/2000 and 8/2001). 
Human papillomaviruses (HPV)
STIKO recommends routine vaccination against HPV (types 
16 and 18) for all girls aged 9 – 14 years to reduce the burden 
of disease due to cervical cancer. Missing HPV vaccinations 
should be completed before the age of 18 years (that is, the 
day before the 18th birthday). The vaccination series should 
be completed before first sexual intercourse. Currently, a 
2-dose scheme is licensed for children aged between 9 – 13 
years (Gardasil®) or 9 – 14 years (Cervarix®, Gardasil®9), 
with an administration interval of 6 months between the 2 
doses. A 3rd dose is necessary for catch-up vaccinations at the 
age of > 13 years and > 14 years, respectively, or if the time 
intervals between the 1st and 2nd dose was < 6 months and 
< 5 months, respectively. Regarding the number of necessary 
vaccine doses as well as the required time intervals between 
vaccinations, STIKO refers to the respective Summary of 
Product Characteristics. 
Since April 2016 the nonavalent HPV vaccine Gardasil®9 
is available on the market in Germany in addition to 
Cervarix® and Gardasil®. All three vaccine products can 
be used to obtain the goal of reducing the incidence of 
cervical cancer and pre-cancer lesions. Once a vaccination 
series is started, it should be completed with the same vac- 
cine product if possible. Further details on the use of HPV 
vaccines can be found under Epid. Bull. 16/2016 (www.rki.
de > Infektionsschutz > Epidemiologisches Bulletin > issue 
16/2016): “Statement of STIKO at RKI: Use of the nonava-
lent vaccine against human papillomaviruses (HPV)“.  
HPV vaccination should be utilised as an opportunity 
to bring other vaccinations for adolescents recommended 
by STIKO up to date. Concerning simultaneous adminis-
tration with other vaccines, STIKO refers to the respective 
Summary of Product Characteristics.
Women who are older than 17 years and have not 
received a HPV vaccination can also benefit from vaccina-
tion against HPV. It is within the physician’s responsibility 
to point this out to patients after an individual risk-benefit 
assessment based on the vaccine licensure.
Vaccinated persons must be informed that vaccination 
with one of the currently available vaccines against human 
papilloma viruses does not protect against all potentially 
oncogenic HPV types and that they must therefore still 
make use of cervical cancer screening services. A scienti-
fic evaluation of the changed HPV vaccination recommen-
dation, supplemental to the scientific rationale (Epid. Bull. 
3.2. Notes on recommended vaccinations
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12/2007)7 and the assessment of vaccination (Epid. Bull. 
32/2009)6 was published in Epid. Bull. 36/2014 5 (www.rki.
de > Infektionsschutz > Epidemiologisches Bulletin > issues 
12/2007, 32/2009, 36/2014).
Influenza
STIKO recommends annual vaccination in autumn with the 
current antigen combination recommended by the WHO 
as a standard vaccination for all persons aged 60 years and 
older, and where indicated in specific groups of persons (see 
Table 2, p. 307). Annual vaccination is recommended even 
when the antigen composition of the vaccine is unchanged 
compared with the previous season.
Measles, Mumps, Rubella (MMR)
Vaccination against measles, mumps and rubella should 
be performed with a combination vaccine (MMR vaccine), 
usually at the age of 11 – 14 months. The 2nd MMR vaccina-
tion should be completed by the age of 2 years to attain the 
earliest possible vaccination protection.
The 1st MMR vaccine dose can be administered from 
9 months of age depending on the epidemiological situation, 
especially in the following situations:
 ▶ pending admission to a community facility (e. g. Kita)
 ▶ after contact with measles cases
There are no comprehensive data on the safety and efficacy 
of MMR vaccination in infants younger than 9 months. In 
the event of an outbreak, such infants must primarily be 
protected through immunisation of contact persons in their 
environment. Individual risk-benefit considerations can, 
in exceptional cases, justify vaccination at 6 to 8 months. 
Infants vaccinated between 6 to 8 months of age should 
receive 2 additional doses of MMR vaccine at the age of 11 
to 14 and 15 to 23 months to establish long-term immunity.
Following the contact with measles cases, passive immu-
nisation with immunoglobulins can be considered up to 
6 days after exposition particularly for unprotected people 
with contraindicated vaccination and a high risk of compli-
cations, like infants less than 6 months of age, immunode-
ficient individuals and pregnant women. Infants between 
6 to 8 months of age can receive immunoglobulins after 
individual risk-benefit consideration alternatively to the 1st 
vaccination. After administration of immunoglobulins, the 
MMR vaccination is not reliably effective for 5 – 6 months. 
This should be taken into consideration in the event of an 
indication for immunoglobulin administration (see also 
Epid. Bull. 16/2013 [www.rki.de > Infektionsschutz > Epide-
miologisches Bulletin > issue 16/2016]).
MMR vaccination is also recommended for all adults 
born after 1970 who have an unknown vaccination status, 
are unvaccinated, or have received only one vaccination in 
childhood, especially if they work in the health care or in 
community facilities, or if they care for immunodeficient 
or immunosuppressed individuals (one-time vaccination, 
preferably with an MMR vaccine). A background paper and 
detailed rationale for this recommendation can be found 
in Epid. Bull. 32/201012 (www.rki.de > Infektionsschutz > 
Epidemiologisches Bulletin > issue 32/2010).
Meningococcal B
A vaccine against serotype B meningococcal disease 
(Bexsero®) was licensed in Europe in January 2013 and 
has been available in Germany since December 2013. 
STIKO currently concludes that the available study results 
and resulting evidence are not sufficient for a conclusive 
decision regarding a universal vaccination recommen- 
dation. An updated STIKO comment regarding the sta-
tus of the meningococcal B vaccine assessment was pub- 
lished in Epid. Bull. 36/2014 (www.rki.de > Infektions-
schutz > Epidemiologisches Bulletin > issue 36/2014).
However, STIKO recommends vaccination against sero-
group B meningococci (MenB) in addition to MenACWY 
vaccination for persons with certain underlying diseases. 
(see Table 2, p. 308). Data regarding immunogenicity and 
efficacy of the MenB vaccine in these persons are lacking, 
but the immune response is likely to be weaker and of 
shorter duration than in healthy individuals. In addition, 
as detailed in the Background Paper “Update of menin-
gococcal vaccination recommendations in Germany: Use 
of the serogroup B vaccine in persons at increased risk 
for meningococcal disease“, the risk for IMD varies accor-
ding to the underlying disease in question (see Bundes-
gesundheitsblatt 2015;58:1314 – 43). Persons with terminal 
complement defects and properdin deficiency have by 
far the highest risk – up to 10,000-fold higher than back-
ground risk. IMD risk in persons with asplenia, on the 
other hand, is much lower, around 20- to 30-fold higher 
than background risk. The risk for persons with other 
immune defects, such as HIV infection or hypogamma-
globulinaemia is lower still. Thus the physician should 
base the decision for MenB vaccination on an individual 
risk assessment. 
Meningococcal C
STIKO recommends the earliest possible vaccination 
against serogroup C meningococcal disease with a me-
ningococcal C conjugate vaccine for all children aged 12 
to 23 months. The primary goal of the vaccination is to 
reduce morbidity due to invasive serogroup C meningo-
coccal diseases and sequelae such as hospitalisation, se-
vere complications, disability and death.
In Germany, there is a subsequent and lower disease in-
cidence peak in adolescents. A detailed justification for 
the vaccination recommendation can be found in Epid. 
Bull. 31/2006 17 (www.rki.de > Infektionsschutz > Epide-
miologisches Bulletin > issue 31/2006).
Children aged up to 17 years with missing vaccinations 
should receive a catch-up vaccination. Concerning simulta-
neous administration with other vaccines, STIKO refers to 
the respective Summary of Product Characteristics.
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In addition to this note, the recommendations on vacci-
nation of persons at increased risk should be followed 
(see Table 2, p. 308).
Meningococcal ACWY
A meningococcal vaccination against serogroups ACWY is 
recommended for certain indications (see Table 2, p. 307 
and Table 3, p. 323). In Europe, tetravalent MenACWY con-
jugate vaccines are licensed from the age of 1 (Nimenrix®) 
and 2 years (Menveo®), according to the Summary of Pro-
duct Characteristics (July 1, 2016). In the US, Menveo® is 
licensed for children aged 2 months or older. For protection 
against MenC disease, MenC conjugate vaccines can be ad-
ministered from the age of 2 months onwards. The majori-
ty of IMD cases in infants are due to serogroup B (about 34 
cases annually from 2012 to 2015), followed by serogroup C 
(6 cases annually), while only 0 to 2 cases annually are due 
to serogroups A, W or Y. 
If protection against MenACWY is indicated after the 
first birthday following MenC vaccination in the first year of 
life, a tetravalent conjugate vaccine should be administered. 
Pertussis
Given the epidemiological pertussis situation in Germany 
and the severity of the clinical course of pertussis in infancy, 
it is advisable to start primary immunisation of infants 
and toddlers – at the earliest possible point in time, that is, 
immediately after 2 months of age, and to continue vaccina-
tion in a timely manner. 
Booster vaccinations are recommended at 5 – 6 years of 
age and 9 – 17 years of age. Vaccines with reduced pertus-
sis antigen content (Tdap or Tdap-IPV) are used from 5 – 6 
years of age both for booster vaccinations and, where appli-
cable, for catch-up primary immunisations.
STIKO recommends administering the next due Td vaccine 
for all adults as a one-time Tdap combination vaccination or 
a Tdap-IPV combination vaccination if indicated. Because a 
monovalent pertussis vaccine is no longer available, admi-
nistration of combination vaccines is recommended on the 
respective vaccination dates. If there is an existing indica-
tion for pertussis vaccination, a Tdap combination vaccine 
can be used, even if a Td-containing vaccine has previously 
been administered. A placebo-controlled study has demons-
trated that one of the available Tdap combination vaccines 
can be administered within 1 month after a previous Td vac-
cination without causing increased side effects; see Epid. 
Bull. 33/2009, p. 340 – 341 (www.rki.de > Infektionsschutz > 
Epidemiologisches Bulletin > issue 33/2009).
In the context of recognised pertussis clusters, vaccination 
can also be considered for fully vaccinated children and ado-
lescents in close contact with cases in the household or in 
community facilities, if the last vaccination occurred longer 
than 5 years ago. Before the birth of a child, it is especially 
important that persons in close household contact with and 
carers of the newborn baby be checked for adequate immu-
nological protection against pertussis defined as vaccination 
within the past 10 years (see Table 2, p. 308). 
Pneumococcal disease
Primary immunisation during infancy: The primary goal of 
universal vaccination of all children up to 24 months of age 
with pneumococcal conjugate vaccine is to reduce morbidi-
ty from invasive pneumococcal diseases (IPD) and sequelae 
such as hospitalisation, disability and death. Infants born at 
term should receive 3 vaccine doses at the ages of 2, 4, and 
11 – 14 months (so-called 2+1 scheme). The minimum interval 
between the 1st and 2nd dose is 2 months, and the minimum 
interval between the 2nd and 3rd dose is 6 months. Preterm 
infants (born before 37 completed weeks of gestation) should 
receive a total of 4 vaccine doses at the ages of 2, 3, 4, and 
11 – 14 months (3+1 scheme). The deviant recommendation for 
preterm babies is due to the licensure of the pneumococcal 
conjugate vaccines, which restricts the use of the 2+1 scheme 
to term infants so far (as of July 2016). A detailed justification 
of the pneumococcal vaccine recommendation can be found 
in Epid. Bull. 36/2015 (www.rki.de > Infektionsschutz > 
Epidemiologisches Bulletin > issue 36/2015).
Standard vaccination of older adults: People aged ≥ 60 years 
who do not belong to any of the risk groups listed under “l” 
or “O” in Table 2 (p. 308) are recommended to be vaccina-
ted with the 23-valent pneumococcal polysaccharide vaccine 
(PPSV23; Pneumovax®23; Category “S”).
Indication vaccinations: For people with certain risk factors 
for pneumococcal diseases (Categories “I” and “O”), vaccina-
tion against pneumococcal disease is recommended at any 
age. For those with an immune deficiency or suppression 
(Group 1) as well as for those with an increased risk of pneu-
mococcal meningitis (Group 3), sequential immunisation 
with 13-valent conjugate (PCV13; Prevenar 13®), followed by 
PPSV23 is recommended. For people in Group 2 and for tho-
se with a professional indication, exclusive vaccination with 
PPSV23 is recommended. Only if aged 2 to 15 years, sequen-
tial immunisation should be conducted in Group 2. 
For people who are recommended to have sequential immu-
nisation (PCV13 followed by PPSV23), the following applies:
 ▶ They should receive PPSV23 not earlier than 2 months 
after PCV13 vaccination. From an immunological per-
spective, an interval of 6 to 12 months in between the 2 
vaccines is preferable.
 ▶ If they have already had a PCV13 vaccination, they should 
only be given the PPSV23 vaccination.
 ▶ If they have previously only been given low-valent conjuga-
te vaccines (PCV7 or PCV10), they should receive PCV 13, 
followed by PPSV23.
 ▶ If they have already had a PPSV23 vaccination, a PCV 
vaccination should be administered with a minimum 
interval of 1 year.
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Booster vaccinations: Due to the fact that vaccine-induced 
protection is not permanent, for all groups listed in Table 2, 
STIKO considers it expedient from a medical/epidemiolo-
gical point of view to administer booster vaccinations with 
PPSV23 at intervals of at least 6 years. According to the 
Summary of Product Characteristics (SPC) for PPSV23, how-
ever, “healthy adults should not routinely be given booster 
vaccinations”. “In the case of individuals with an increased 
risk of serious pneumococcal disease,” on the other hand, the 
SPC states that booster vaccinations “could be considered”. 
This regularly applies to people in categories “I” and “O”. 
In respect to seniors who do not belong to either of these 
categories, the indication should be considered on a case- 
by-case basis. Patients must be informed about the increased 
reactogenicity of the booster vaccination in comparison 
with the primary vaccinations as well as the possible loss of 
protection if booster vaccinations are not given.
Detailed scientific justifications for these recommenda-
tions can be found in Epid. Bull. 36/2016 and 37/2016 23,24 
(www.rki.de > Infektionsschutz > Epidemiologisches Bulletin 
> issues 36 and 37/2016).
Poliomyelitis
The oral polio vaccine (OPV) is no longer recommended 
owing to the risk – although very low – of vaccine-associa-
ted paralytic poliomyelitis. For protection against poliomy-
elitis, an injectable vaccine – inactivated polio vaccine (IPV) 
– is recommended. From 9 to 17 years of age, a booster vac-
cination containing IPV is recommended for adolescents. 
Primary immunisation started with OPV is to be completed 
with IPV. Additional information on vaccination against 
poliomyelitis is displayed in Table 2 (see p. 309).
Rotavirus (RV)
The RV vaccines are oral live vaccines. Depending on the 
used vaccine brand, 2 doses (Rotarix®) or 3 doses (Rota-
Teq®) are given to the infant starting at the age of 6 weeks, 
with at least 4 weeks between the vaccine doses. There is a 
possible slightly elevated risk for intussusception (estima- 
ted at 1 – 2 cases per 100,000 infants vaccinated) within 
the 1st week after the 1st RV vaccine dose, which increases 
with age of the vaccinee. Therefore, STIKO strongly recom-
mends beginning the vaccination series as early as possible 
– by the age of 12 weeks at the latest – and to complete 
it preferably by the age of 16 weeks (Rotarix®) or 20 – 22 
weeks (RotaTeq®). The vaccination series must be comple-
ted by the age of 24 weeks when using Rotarix® or at the 
age of 32 weeks when using RotaTeq®.
The background paper and detailed scientific rationale 
can be found in Epid. Bull. 35/201331 (www.rki.de > Infek-
tionsschutz > Epidemiologisches Bulletin > issue 35/2013). 
Concerning simultaneous administration with other vacci-
nes, STIKO refers to the respective Summary of Product 
Characteristics.
RV-immunization is recommended for preterm infants 
at their chronological age and for full-term infants, even if 
hospitalized. The benefits of RV vaccination in neonatal in-
tensive care units (NICU), providing protection against no-
socomial RV-infection, significantly outweigh the low risk 
of RV gastroenteritis in other hospitalized patients through 
nosocomial vaccine virus transmission. The risk of vaccine 
transmission is low and is sufficiently reduced by common 
infection control measures on NICUs. A joint statement of 
the STIKO, the German Academy for Pediatrics and Ado-
lescent Medicine (DAKJ) and the German Society for Neo-
natology and Pediatric Intensive Care Medicine (GNPI) on 
RV-vaccination of preterm infants and neonates during hos-
pitalization is published in Epid. Bull. 1/2015 (www.rki.de > 
Infektionsschutz > Epidemiologisches Bulletin > issue 1/2015).
Tetanus 
Each booster vaccination with Td (including in case of an in-
jury) should be used as a reason to check whether pertussis 
vaccination is indicated and, if applicable, to administer a 
combination vaccine (Tdap).
Tick-Borne Encephalitis (TBE)
TBE illnesses in children generally have a milder course 
than in adults, predominantly presenting symptoms of me-
ningitis and more rarely symptoms of encephalitis. Resi-
dual neurological damage has been reported only in isola-
ted cases. As febrile reactions of > 38°C have been observed 
in 15 % of 1- to 2-year-old vaccinated children (as opposed 
to 5 % of 3- to 11-year-old children), the recommendation is 
to carry out a particularly careful assessment of the indi- 
cations together with the parents prior to vaccination 
of children under 3 years of age. Otherwise, the basic 
principles of indicated vaccination presented in Table 2, p. 
309, apply to the paediatric vaccine and to the adult vac-
cine, including the information contained in the Table on 
risk areas and on the seasonality of the disease. In addition, 
vaccination should be completed by the beginning of the 
tick season – about 95 % of cases are notified in the months 
of May to November.
Varicella
The 1st dose of the vaccination against varicella (V) is gene-
rally administered at age 11 to 14 months, either at the same 
time as the 1st MMR vaccination or, at the earliest, 4 weeks 
after it. For the 1st vaccine dose against varicella and MMR, 
the simultaneous application of a single varicella vaccine 
dose and an MMR combination vaccine at different body 
sites is preferable. The rationale for this recommendation 
is a slightly increased risk of febrile seizures 5 – 12 days after 
application of the combined MMR-varicella (MMRV) vacci-
ne compared with the simultaneous vaccination with a vari-
cella and MMR vaccine. This increased risk was only obser-
ved after the 1st vaccination. The 2nd dose of varicella vaccine 
should be administered between ages 15 to 23 months and 
can be conducted with a MMRV combination vaccine; see 
the STIKO statement on “Combined vaccination against 
measles, mumps, rubella and varicella (MMRV)” in Epid. 
Bull. 38/2011 (www.rki.de > Infektionsschutz > Epidemiolo-
gisches Bulletin > issue 38/2011).
In all non-vaccinated 9- to 17-year-old adolescents with 
no history of varicella, catch-up vaccination should also 
take place with 2 doses, in accordance with the Summary of 
Product Characteristics. The minimum interval between 2 
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doses of varicella or MMRV vaccine is 4 to 6 weeks (depen-
ding on the Summary of Product Characteristics provided 
by the manufacturer). Children and adolescents who have 
only been vaccinated once against varicella should receive a 
2nd dose of varicella or MMRV vaccine.
The background paper and detailed scientific rationale 
for the varicella vaccination recommendation was pub-
lished in Epid. Bull. 32/200934, and an evaluation of the 
recent varicella vaccination strategy is found in Epid. Bull. 
1/2013 (www.rki.de > Infektionsschutz > Epidemiologisches 
Bulletin > issues 32/2009 and 1/2013).
Yellow fever
Yellow fever vaccination is recommended when traveling to 
countries where yellow fever is endemic and is necessary in 
countries that require proof of yellow fever vaccination as a 
condition of entry. After reviewing the available evidence, 
World Health Organization (WHO) has declared in 2014 
that a single dose of yellow fever vaccine provides lifelong 
protection. The current regulation that a certificate of yellow 
fever vaccination is valid for a period of 10 years and a boos-
ter vaccination is necessary afterwards can be omitted. The 
change extending the validity of a certificate of vaccination 
against yellow fever from 10 years to lifelong has come into 
force in July 2016. It may be possible that the implemen-
tation in some countries will be delayed and a certificate 
not older than 10 years is still required. Updates of current 
entry requirements can be found on the WHO web site: 
www.who.int/entity/ith/2016-ith-county-list.pdf?ua=1//; 
www.who.int/entity/ith/2016-ith-annex1.pdf?ua=1. 
Following persons may benefit from a booster dose because 
their immune response may be weakened and therefore 
a protection after a single vaccination will eventually not 
last lifelong: (1) children who were vaccinated for the first 
time at the age < 2 years, especially those who have been 
vaccinated against yellow fever and MMR simultaneously, 
(2) women who have been vaccinated during pregnancy, 
(3) HIV-infected people (4) individuals who get yellow fever 
vaccination and MMR vaccination simultaneously. 
The detailed scientific rationale for the adaption of the 
yellow fever vaccination recommendation can be found 
in Epid. Bull. 35/2015 2 (www.rki.de > Infektionsschutz > 
Epidemiologisches Bulletin > issue 35/2015).
General information
Providing information is an important part of the immu-
nisation service offered by the physician. The physician’s 
obligation to provide the patient or person to be vaccinated 
with information was re-defined in 2013 in the “Law on the 
Improvement of Patients’ Rights” (Patient Protection Act) 
(German Civil Code [BGB], Art. 1 § 630 e). Before admi-
nistering a vaccine, the physician is obliged to inform the 
vaccinee or their accompanying parent or guardian about 
the disease to be prevented and the vaccination itself so 
that they can make an informed decision about receiving 
the vaccine or not. This information should include: back-
ground on the disease to be prevented and treatment op-
tions, information on the benefits of the vaccination, the 
contraindications, information on how the vaccination is 
administered, when vaccination protection starts and how 
long it lasts, how the recipient should behave after immu-
nisation, potential adverse effects and complications (see. 
Epid. Bull. 25/2007, www.rki.de > Infektionsschutz > Epide-
miologisches Bulletin > issue 25/2007) as well as the neces-
sity for follow-up and booster vaccinations and when they 
should be administered. The information must be provided 
verbally in accordance with § 630 e, para. 2, no. 1, BGB, 
by the person administering the vaccination or by a person 
who has received the training required to carry out the mea-
sure; additional reference may be made to written informa-
tion given to the patient. Care must be given to ensuring 
that the information is provided in good time and in a way 
that the person being vaccinated or their accompanying pa-
rent or guardian can understand the content. Information 
may be given immediately before immunisation provided 
that the patient or the accompanying parent or guardian is 
not under pressure to make a decision.
In the case of public vaccination appointments, it is recom-
mended to provide information in written form in advance 
and, if appropriate, acquire a written declaration of con-
sent. This does not, however, absolve the physician from 
the legal obligation to provide the person being immunised 
or their accompanying parent or guardian with verbal in-
formation, as well, in order to give them the opportunity 
to ask questions. In the justification of the law (Bundestag 
printed paper 17/10488, p. 24, on § 630 e, BGB), this point 
is explained as follows: “The patient should be given the 
opportunity to ask questions during a face-to-face discus-
sion with the person administering the treatment so that 
the information provided is not reduced to simply ticking a 
box on an information sheet.” Information sheets on vacci-
nations by registered physicians are available free of char-
ge on the website of the “Forum for vaccinating doctors” 
(www.forum-impfen.de, after password-protected registra-
tion). In some cases, information sheets are sold by vari-
ous providers (e. g. the German Green Cross). RKI offers 
translations of information sheets on many different vac-
cinations to download free of charge in up to 19 languages 
(www.rki.de > Infektionsschutz > Impfen > Informations-
materialien in verschiedenen Sprachen).
The leaflets also contain a questionnaire on the state 
of health of the person being vaccinated and on previous 
immunisations which specifically relate to the vaccine 
4. Practical issues related to the application of vaccines   
4.1. Obligation to provide information prior to immunisation 
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under consideration. Subsequently, the physician must 
offer an opportunity to address any questions and issues 
raised by the person being vaccinated or their parent or 
guardian. The information sheets include a declaration of 
consent which can be signed by the person being vaccina-
ted or their parent or guardian. Written consent is not re-
quired by law, i.e. it is sufficient if a verbal consent is noted 
in the patient’s files. In certain cases, however, a written 
declaration of consent can be useful. In the case of minors, 
the parent’s or guardian’s consent must be routinely obtai-
ned. Adolescents can give their own consent if they have ac-
quired the necessary cognitive and decision-making ability; 
this is usually the case at 16 years of age. The vaccinating 
physician should also note in the patient’s files that the in-
formation has been provided. If the information is based 
on the relevant information sheet, the vaccinating physici-
an should draw attention to this in his files. In this case, 
too, the person being vaccinated or the parent or guardian 
must be given an opportunity to ask questions. Moreover, 
it can be useful to make a note in the patient’s file if the 
relevant person or the parent or guardian has refused a 
vaccination. To support the counselling of patients who do 
not speak German, RKI has published – in addition to the 
translations of information sheets and consent forms – the 
national vaccination schedule in 20 languages (www.rki.de 
> Infektionsschutz > Impfen > Informationsmaterialien in 
verschiedenen Sprachen). 
Off-label use
The term “off-label use” refers to the prescription of a 
licensed medical product outside of the use for which licen-
sure had been applied and approved by national or Euro-
pean regulatory authorities, for example in respect to the 
scope of application (indication), dosage, or duration of 
treatment. In case of off-label use, the physician is liable for 
the medical appropriateness of the treatment as well as for 
potential adverse events. Medical associations recommend 
that off-label use should only be conducted based on valid 
guidelines or recommendations or acknowledged scientific 
literature. For off-label use, it is indispensable to compre-
hensively inform the patient or legal guardian of risks and 
benefits of the respective vaccination, and that the vaccine 
is being used off-label. Medical treatment and provided 
information have to be documented comprehensively in the 
patient’s file.
Contraindications
Children, adolescents, and adults with acute diseases 
requiring treatment should only be vaccinated after reco-
very, with the exception of post-exposure vaccination.
Depending on the diagnosis, adverse events temporally cor-
related with a vaccination are not an absolute contraindi-
cation against a second vaccination with the same vaccine. 
Obstacles to vaccination can include allergies to compo-
nents of the vaccine. Neomycin and streptomycin are im-
portant considerations, as well as egg protein in rare cases. 
Persons who react with anaphylactic symptoms after oral 
consumption of egg protein should not be vaccinated with 
vaccines that contain egg protein (yellow fever and influen-
za vaccine).
In the case of congenital or acquired immunodeficiency, 
the physician treating the immunodeficiency should be 
consulted before vaccination with a live vaccine. Serological 
monitoring of the success of vaccination is indicated in pa-
tients with immunodeficiency. 
Vaccinations that are not urgently indicated should not be 
carried out during pregnancy. Live vaccines against meas-
les, mumps, rubella, and varicella are contraindicated in 
pregnancy. It is allowed to administer a yellow fever vacci-
nation in pregnancy in case of clear indication and merely 
after careful risk-benefit consideration. A yellow fever vac-
cination should not be carried out out in breastfeeding wo-
men. Worldwide there are reported sporadic cases of breast-
fed infants who came down with a meningoencephalitis 
after their mother had received a yellow fever vaccination.
False contraindications
Indicated vaccinations are often omitted because certain 
conditions are erroneously considered contraindications. 
These include:
 ▶ Commonplace infections, even if they are associated 
with subfebrile temperatures (< 38.5 °C);
 ▶ Possible contact of the person to be vaccinated with 
people with contagious diseases;
 ▶ Seizures in the family;
 ▶ Febrile convulsions in the medical history of the child to 
be vaccinated (as febrile vaccination reactions can provo-
ke seizures, administering antipyretics to children who 
are prone to seizures should be considered, for example, 
in the case of inactivated vaccines, at the time of vacci-
nation and again 4 and 8 hours after the vaccination, 
as well as between the 7th and 12th day following MMR 
vaccination in the case of a rise in temperature);
 ▶ Eczema including dermatoses and localised skin 
infections;
 ▶ Treatment with antibiotics or with low doses of corticos-
teroids or locally applied steroid-containing preparations;
 ▶ Pregnancy of the mother of the child to be vaccinated 
(including varicella vaccination after risk assessment; 
see below*);
 ▶ Congenital or acquired immunodeficiencies upon 
vaccination with inactivated vaccines;
 ▶ Neonatal jaundice;
 ▶ Premature birth: premature babies should be vaccinated 
according to the recommended vaccination age regard-
less of their age of maturity and current weight;
 ▶ Breastfeeding women: they can receive every required 
vaccination except a yellow fever vaccination (see above: 
Contraindications);
* Currently, the risk of connatal varicella syndrome in a seronegative pregnant 
woman in contact with her non-vaccinated child thus at risk of being infected 
is greater than the risk of such a complication through vaccination and, where 
applicable, transmission of vaccine-induced varicella via her child.
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 ▶ Breastfed infants: infants who are exclusively or 
partially breastfed can be vaccinated in accordance with the 
STIKO recommendations just the same as infants who 
are fed formula or other baby food.
Indicated vaccinations should also be undertaken in persons 
with chronic diseases, as these persons are especially endan-
gered by severe courses and complications of vaccine-preven-
table diseases. Persons with chronic diseases should be edu-
cated on the benefits of vaccination compared with the risk of 
disease. There is no evidence that flare-ups or progressions 
of chronic diseases, which may occur in temporal association 
with vaccination, can be causally linked to vaccination.
4.2. Intervals between vaccinations
General information
The vaccination intervals shown in Tables 1, 2, and 7 and in 
Summary of Product Characteristics sheets should generally 
be complied with and neither be shortened nor prolonged. 
In the case of urgently indicated vaccinations, such as 
post-exposure rabies prophylaxis or postnatal immunopro-
phylaxis of hepatitis B in the newborn, the recommended 
vaccination schedule must be strictly adhered to. Minimum 
intervals should be shortened only in urgent exceptional 
cases (for example, a trip abroad at short notice). 
For long-lasting vaccination protection it is particularly 
important that, during the primary immunisation, the 
recommended minimum interval between the second-
to-last and last vaccination (generally 6 months) is not 
shortened.
On the other hand, every vaccine dose counts! Additional 
vaccine doses are not required if intervals between already 
administered vaccine doses are longer than recommended. 
Even a primary immunisation that has been out of date for 
many years or a booster vaccination not carried out in a 
timely manner, for example against diphtheria, tetanus, 
poliomyelitis, hepatitis B, or TBE (see www.rki.de > Infek-
tionskrankheiten > FSME > Antworten auf häufig gestell-
te Fragen zur FSME-Impfung), does not have to be started 
again from the beginning, but is updated with the missing 
vaccine doses. This also applies to infants and toddlers. In 
the interest of providing vaccination protection as early as 
possible, exceeding the recommended vaccination intervals 
should be avoided in young children.
The following applies to intervals between different vacci-
nations: Live vaccines (attenuated, replication-competent 
viruses or bacteria) can be administered simultaneously. If 
they are not administered simultaneously, there must be a 
minimum interval of 4 weeks between the 2 vaccine admi-
nistrations. In the case of immunisation with inactivated 
vaccines (inactivated pathogens, their antigen components, 
and toxoids) no minimum time interval between 2 vacci-
nations is necessary, even if one of the vaccines is a live 
attenuated vaccine. Possible adverse reactions following 
preceding vaccinations should have completely subsided 
prior to a new vaccination. With regard to the minimum 
interval between 2 vaccinations as well as the co-adminis-
tration of vaccine, note should be taken of the Summary of 
Product Characteristics for the respective vaccine.
Interval between vaccination and surgical interventions
If the indication is urgent, surgical procedures can be car-
ried out at any time, even if preceded by a vaccination. In 
the case of elective procedures, a minimum interval of 3 
days should be allowed after the administration of inacti-
vated vaccines and a minimum interval of 14 days after the 
administration of live vaccines.
Neither clinical observations nor theoretical considera-
tions suggest that vaccinations and surgical procedures are 
incompatible. However, to distinguish between possible vac-
cination reactions and surgical complications, it is recom-
mended that these minimum intervals between vaccinations 
and operations be maintained. 
With the exception of vital vaccinations (such as tetanus, ra-
bies, and hepatitis B vaccination), these minimum intervals 
also apply to vaccination following major surgical procedu-
res. Following operations associated with immunosuppres-
sive treatment, e. g., transplantations, vaccinations must be 
planned in cooperation with the attending physician.
4.3. Shortages of vaccines
Since October 2015, the Paul Ehrlich Institute (PEI) has in-
cluded information about shortages in the supply of vacci-
nes and the probable delivery waiting times on its website 
(www.pei.de/lieferengpaesse-impfstoffe-human). This in-
formation derives from notifications from pharmaceutical 
companies which report shortages as soon as the delivery 
chain for supplying a vaccine is broken for a period of at 
least 2 weeks. In agreement with RKI and STIKO, PEI also 
announces which alternative vaccines with the same com-
position are available and can be used.
If no vaccines with the same antigenic composition are 
available, STIKO is being asked to recommend a course of 
action involving the use of other vaccines which can also 
achieve the required immunity (www.rki.de > Kommissio-
nen > Ständige Impfkommission > Lieferengpässe).
Unavailability of Tdap and IPV vaccines  
The supply of Tdap and Tdap-IPV vaccines is particularly 
challenging because of increased demand worldwide for 
acellular pertussis vaccine and inactivated polio vaccine. As 
production capacity cannot keep pace, this situation could 
continue for several years. STIKO has published a state-
ment on the issue entitled “Handlungsempfehlungen bei 
Nicht-Verfügbarkeit von Tdap- bzw. IPV-haltigen Impfstof-
fen” (Recommendations in case of unavailability of Tdap- or 
IPV-containing vaccines) Epid. Bull. 14/2016 (www.rki.de 
> Infektionsschutz > Epidemiologisches Bulletin > issue 
14/2016). This describes basic procedure if there is a shor-
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tage of these vaccines and how the groups of individuals to 
be vaccinated can be prioritised.
4.4. Handling of vaccines and procedure during vaccination
Vaccines are sensitive biological products that must be espe-
cially protected from a rise in temperature. Vaccines contai-
ning replication-competent viruses are particularly sensitive. 
All vaccines should be stored in the refrigerator at 2 – 8°C. 
The storage temperature must be checked regularly. Vacci-
nes that, by mistake, were stored incorrectly or frozen must 
be discarded. Vaccines should not come into contact with 
disinfectants. The stoppers of injection vials must be dry!
The needle should be dry; in particular, the outside of the 
cannula should not become wet with vaccine. This causes 
the injection to be painful and can lead to inflammation in 
the region of the injection canal. After drawing the vaccine 
into the syringe and removing any air that might be present, 
a new needle should be fitted for the injection. The injection 
site must be disinfected prior to injection. The skin should 
be dry again at the time of injection.
For vaccines injected via the intramuscular route, the pre-
ferred injection site is the deltoid muscle. If this muscle is 
not sufficiently developed, injection into the vastus lateralis 
muscle (anterolateral thigh) is recommended. The risk of in-
jury to nerves or vessels there is low. Injection of adsorbate 
vaccines into the subcutaneous fatty tissue can lead to pain-
ful inflammations and to the formation of granulomas 
or cysts. In addition, there is doubt about the success of 
vaccinations when injected into fatty tissue.
4.5.  Guidance on reducing vaccination-related pain and 
 stress
Background
It is not unusual for pain and stress reactions to be trigge-
red when vaccines are injected. Fear or worry about poten-
tial pain can have a lifelong negative impact on attitudes to 
visiting the doctor, vaccinations and the acceptance of vacci-
nations both amongst children and their parents.
Nowadays, there are several evidence-based sets of re-
commendations for reducing pain and stress connected 
with vaccinations. These include certain injection tech-
niques, age-related distraction methods and other beha-
viours which can lessen the pain of vaccination. These re-
commendations are summarised in the following. Physici-
ans are encouraged to apply these techniques on reducing 
vaccination-related pain in their everyday practice and thus 
to promote public acceptance of vaccination. Additional in-
formation can be found in the publications cited.1-6
General recommendations
 ▶ During vaccination, healthcare professionals should be 
calm, cooperative and competent. When describing the 
vaccination procedure to the person being vaccinated, it 
is important to use neutral language and choose words 
carefully in order to avoid increasing the individual’s fear or 
suspicion. It is essential to avoid using falsely reassuring or 
dishonest phrases like “It won’t hurt at all!”
Painkillers
 ▶ In individual cases, lidocaine patches or creams un-
der occlusive dressing can be used for children from 
4 months to < 12 years of age to reduce the pain caused by 
the injection. In children aged < 12 months, the patches 
and creams should not be used concomitantly with drugs 
like sulphonamide which contributes to the formation 
of methaemoglobin. Pain patches can also be helpful for 
adolescents and adults who are afraid of injections. 
 ▶ The minimum time of 30 – 60 minutes to achieve the 
optimal pain relief must be taken into account during 
planning. The costs of the patches (approx. € 5 each), 
which are freely available in pharmacies, usually have to 
be borne by the parents or the person being vaccinated.
 ▶ To reduce pain an ice spray can also be used. It should be 
sprayed for 2 – 8 seconds; after disinfection, the vaccina-
tion can be administered immediately. 
Other support procedures
 ▶ Even before their children’s first vaccination appointment 
(from 2 months of age), parents should be informed about 
the forthcoming vaccinations and the concomitant pain 
and pain-reducing options. This means that the informa-
tion could already been given at the U3 examination in 
order to promote the use of pain-reducing strategies at the 
vaccination appointment itself. 
 ▶ Parents of children aged <10 years should be present in 
the room during their child’s vaccination.
 ▶ Children aged ≥ 3 as well as adolescents and adults should 
receive information about what will happen during the 
vaccination and how they can best deal with pain or fear, 
e. g. by clasping their mother’s or father’s hand immedi-
ately before the injection. Children aged ≤ 6 should have 
their attention diverted from the pain by suitable tactics 
(e. g. blowing up a balloon, pinwheels, blowing bubbles, 
toys, videos, conversations or music) immediately before 
and after the injection. To distract adults, they can be en-
couraged to cough slightly or hold their breath.
Recommended body position
 ▶ Sucking on a dummy will also help to reduce pain in 
infants.
 ▶ If infants are still being breastfed, mothers can nurse 
them during the vaccination. If, however, the infant is 
being vaccinated against rotavirus at the same time, the 
mother should not breastfeed before and during the RV 
vaccination because concurrent breastfeeding can poten-
tially weaken the effect of the RV vaccination (see FAQ 
on rotavirus vaccination and breastfeeding Epid. Bull. 
39/2013, www.rki.de > Infektionsschutz > Epidemiologi-
sches Bulletin > issue 39/2013). Alternatively, a dummy 
can be used.
 ▶ Children aged < 2 who are no longer being breastfed 
can be given 2 ml of 25 % glucose solution or another 
sweetened liquid a minute or two before the vaccination. 
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As rotavirus vaccines contain sucrose, it should be given 
first if it is one of several vaccinations being administe-
red at the same time.
 ▶ Small children aged < 3 should preferably be carried or 
sit on their parents’ lap during the vaccination and be 
gently rocked and stroked afterwards.
 ▶ Children aged ≥ 3 as well as adolescents and adults 
should sit as upright as possible during the vaccination. 
Children can sit on their parents’ laps so that their pa-
rents can help to keep their limbs still.
 ▶ People who have experienced fainting during vaccina-
tions or other medical interventions should be vaccina-
ted lying down.
Recommended injecting techniques
 ▶ For infants aged < 2 months, the length of the needle 
should be 15 mm; for older infants and small children 
25 mm and for adolescents and adults 25 – 50 mm.
 ▶ Irrespective of age, intramuscular injections should be 
administered without aspiration. Aspiration is unneces-
sary because there are no major blood vessels (M. vastus 
lateralis or M. deltoideus) in the parts of the body that 
are used for the injection.
 ▶ If several vaccinations are being given at the same time, 
the most painful injection should be given last. Pneumo-
coccal and MMR injections can be particularly painful.
Pain-reducing techniques that are not recommended
 ▶ Warming the vaccine
 ▶ Manual stimulation of the area to be injected, e. g. by 
rubbing or pinching
 ▶ Administering oral analgesics before or during the vac-
cination
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4.6. Documentation of the vaccination
General information
The batch number, vaccine name (brand), date of vaccinati-
on and disease vaccinated against must be documented in 
the patient’s vaccination card and in the medical record of 
the physician administering the vaccine, in accordance with 
the specifications of the IfSG § 22. The stamp and signature 
of the physician are likewise part of the vaccination docu-
mentation. This applies to all vaccines and can make retro-
spective investigation easier, should questions arise about 
the efficacy and safety of particular vaccines or individual 
vaccine batches. Any form that meets WHO requirements 
and that also makes allowance for the provisions of the IfSG, 
such as “International certificates of vaccinations and shot 
record”, can be used as a vaccination card.
Annex 2 of the immunisation guideline of the Federal 
Joint Committee (G-BA) designates a standard documenta-
tion code for vaccinations that has had to be used since 1 July 
2008 when billing statutory health insurance companies.
Missing vaccination documentation 
The physician is frequently confronted with missing, un-
traceable or incomplete vaccination documents. This 
is not a reason for postponing necessary vaccinations, 
not catching up on missing vaccinations, or not starting 
primary immunisation. No particular risk arises from ad-
ditional vaccinations when vaccine-induced protection 
already exists. This also applies to multiple vaccinations 
with live virus vaccines. Serological tests to check the 
immune status of an individual are indicated only in excep-
tional cases (e. g., anti-HBs antibodies for persons at incre-
ased risk of hepatitis B infection); serological tests to detect 
previous vaccinations in the case of unclear vaccination 
status are generally not useful.
4.7. Vaccine-associated complications
Criteria for differentiating normal vaccine reactions from 
potential complications
In accordance with the Protection Against Infection Act 
(IfSG) (§ 6 para.1, no.3), every vaccinating physician is re-
quired to notify the responsible health authority if the sus-
picion of vaccine-associated complications arises. Such 
complications are defined as damage to health that goes 
beyond the usual dimensions of a reaction to vaccination. In 
order to differentiate vaccination-associated complications, 
which must be reported, from normal vaccination reactions, 
STIKO has defined the characteristics of normal reactions 
to vaccination, as requested by IfSG (§ 20, para. 2).  
Normal vaccination reactions that are exempted from 
notification are defined as temporary local and general re-
actions that do not go beyond the usual dimensions of a 
reaction to vaccination and can be seen as the expression 
of the organism’s interaction with the vaccine. STIKO has 
elaborated the following criteria for normal reactions to 
vaccines:
 ▶ over a period of 1 – 3 days (occasionally longer): prolonged 
reddening, swelling or pain around the injection site,
 ▶ over a period of 1 – 3 days: fever < 39.5°C (rectal measu-
rement), headache and joint pain, tiredness, discomfort, 
nausea, restlessness, swelling of regional lymph nodes,
 ▶ 1 – 3 weeks after administration of attenuated live vac-
cines: symptoms of an ascribable “vaccination illness” 
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such as mild parotid swelling, short-term arthralgia or a 
temporary exanthema after measles, mumps, rubella or 
varicella vaccinations, or mild gastrointestinal pain, e. g. 
following rotavirus or typhoid vaccinations.
Also exempted from notification are symptoms which are 
obviously ascribable to a cause other than the vaccine; all 
other reactions should be reported.
Reporting the suspicion of vaccine-associated complications
In accordance with the Protection Against Infection Act 
(IfSG) (§ 6 para.1, no.3), the suspicion of damage to health 
(suspicion of vaccine-associated complications) that goes 
beyond the normal dimensions of vaccine reactions must 
be reported to health authorities. The respective physician’s 
notification must immediately be forwarded by the health 
authorities to the relevant state authorities in accordance 
with § 11, para. 2 (IfSG) and from there to the respective fe-
deral authorities (Paul Ehrlich Institute, PEI) in accordance 
with § 77 of the German Drug Law. The notification obliga-
tion was made statutory in order to immediately trigger the 
relevant immunological tests (e. g. to exclude an immune 
defect) or microbiological tests (e. g. to exclude an intercur-
rent infection by differential diagnosis) required to clarify 
adverse drug reactions and to acquire and store the neces-
sary test materials such as serum or stool samples.
The notification obligation applies irrespective of whether 
or not the vaccine under discussion is publicly recommen-
ded. In order to ensure uniform reporting of a suspected 
case nationwide, PEI has developed a report form in colla-
boration with STIKO and the Ministry of Health entitled, 
“Bericht über Verdachtsfälle einer über das übliche Aus-
maß einer Impfreaktion hinausgehenden gesundheitli-
chen Schädigung” (Report on suspected cases of damage 
to health going beyond the usual dimensions of a reaction 
to vaccination) which is available online at www.pei.de/
SharedDocs/Downloads/vigilanz/pharmakovigilanz/ifsg-
meldebogen-verdacht-impfkomplikation.html or can be ob-
tained from the health authorities. The reports help to im-
prove the pool of data on vaccine-associated complications. 
In addition, the health authorities should inform the per-
son concerned or the parent or guardian about the statutory 
provisions for compensating the victims of vaccine-related 
damage (§§ 60 – 64 IfSG). The relevant application should 
be made to the appropriate pension office.
In addition, pursuant to § 6 of their professional code, 
physicians are obliged to report any adverse drug reactions 
they encounter in the course of conducting treatment to 
the Drug Commission of the German Medical Association 
(www.akdae.de > Arzneimittelsicherheit > Unerwünschte 
Arzneimittelwirkung melden). The manufacturer can also 
be informed.
4.8. Information on cost coverage of immunisations
There are various possible payers for covering the cost of 
vaccinations. New regulations were established in 2007 
that define which vaccinations are covered by all statutory 
health insurance companies in Germany. According to 
§ 20d of Book V of the Social Code [SGBV], insured per-
sons are entitled to vaccination pursuant to § 2 no. 9 of the 
Protection Against Infection Act (IfSG). Based on STIKO 
recommendations, the Federal Joint Committee (G-BA) must 
determine, in a vaccination guideline (see www.g-ba.de), 
the details of the obligation to reimburse the cost of 
vaccinations (including requirements, type and scope). In 
doing so the particular significance of vaccinations for pu-
blic health should be taken into account. Immunisations 
indicated owing to an increased health risk from a non-
work-related stay abroad (travel vaccinations) are excluded 
from this entitlement, unless, for the protection of public 
health, there is special interest in preventing the introduc-
tion of a transmissible disease into the Federal Republic 
of Germany (for example, travel vaccinations). If a GB-A 
decision is not made within 3 months following publication 
of the STIKO recommendations, those vaccinations recom-
mended by STIKO must be provided by health insurance 
companies until the guideline comes into existence.
Health insurance companies can also include in their 
optional benefits coverage the reimbursement of the cost 
for further vaccinations that are not part of the guideline 
of the Federal Joint Committee. In addition, the health in-
surance company associations have to jointly and uniform-
ly make agreements regulating the funding of protective 
vaccinations and the reimbursement of vaccine costs at the 
regional level with the regional authorities responsible for 
carrying out vaccinations.
Apart from the health insurance companies, other payers 
are able to cover the cost of protective vaccinations. These 
include the Public Health Service [Öffentlicher Gesund-
heitsdienst (ÖGD)] for vaccinations pursuant to § 20 (5) of 
the IfSG, as well as other named entities based on legal re-
gulations (e. g., employers). For example, in accordance with 
§ 3 (3) of the Occupational Safety and Health Act [Arbeits-
schutzgesetz], an employer is not permitted to impose the 
costs of occupational safety measures on an employee. Oc-
cupational safety measures include vaccinations that must 
be offered in accordance with the Occupational Safety and 
Health Act [Arbeitsschutzgesetz]/Biological Agents Ordi-
nance [Biostoffverordnung]/Regulation Concerning Occu-
pational Healthcare [Verordnung zur arbeitsmedizinischen 
Vorsorge (ArbMedVV)]. The vaccinations offered are specifi-
cally determined by the outcome of a risk assessment.
The vaccinations denoted “O” in the STIKO recommen-
dations also include those for professional groups that 
are not subject to the named ordinances. In this category, 
vaccinations are also listed that are primarily indicated for 
the protection of third parties.
Even if the named regulations do not apply in these cases, it 
is in the interests of the employer concerned to offer these 
vaccinations, because in doing so the employer can counter 
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possible claims for redress or save on the costs of down-
time among employees. How far the recommendations 
denoted “O” are standard services for the statutory health 
insurance companies is determined by the protective 
vaccination guidelines of the Federal Joint Committee. At 
present, this does not regularly provide for an entitlement 
to statutory health insurance company reimbursement 
in cases where the employer is responsible. However, for 
vaccinations recommended by STIKO that do not have to 
be covered by the employer, the statutory health insurance 
companies are obligated to reimburse the cost, based on 
the vaccination guideline.
4.9.  Vaccination recommendations for immigrants,  
 refugees, or asylum seekers in communal  
 accommodation
It is recommended to begin immunising residents of com-
munal accommodation as soon as possible through the 
ÖGD or through physicians commissioned by the ÖGD. 
Primary immunisation should be completed by private 
physicians in the most recent place of residence or by the 
ÖGD after leaving communal accommodation.
Available vaccination documentation should, where possi-
ble, be taken into account; the procedure should be based 
on the STIKO recommendations.
 ▶ Unvaccinated adults and adults with unclear vaccinati-
on status should receive vaccinations against diphtheria 
and tetanus, against poliomyelitis and, in seronegative 
persons, against hepatitis B. Adults should receive the 
next due Td vaccination (booster vaccination) as a one-
time Tdap combination vaccination. Individuals born 
after 1970 should be vaccinated once against measles 
(MMR). Women of childbearing age should receive 
2 vaccinations against rubella (MMR), and seronegative 
women who wish to conceive should be vaccinated twice 
against varicella. It is recommended that persons over 
the age of 60 receive a pneumococcal vaccination and 
each autumn an annual influenza vaccination.
 ▶ Unvaccinated children and children with unclear vacci-
nation status should receive vaccinations against diph-
theria, tetanus, and pertussis, as well as against polio-
myelitis, measles, mumps, rubella, varicella, hepatitis 
B, meningococcal C, and HPV (girls only); in addition, 
infants and toddlers should be vaccinated against rota-
virus, Haemophilus influenzae type b, and pneumococci.
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5.  Information on post-exposure vaccinations or other measures of specific prophylaxis  
 of communicable diseases
5.1. Overview
In addition to the recommendations for standard and 
indicated vaccinations, STIKO issues recommendations 
regarding post-exposure vaccinations and other measures 
of specific prophylaxis of contact persons in private and 
occupational settings and in community facilities. Those 
recommendations include advice on how insufficiently- 
protected individuals can be protected after exposure to spe-
cific infectious agents in order to prevent further spread of the 
disease or to mitigate the course of the disease. Post-exposure 
vaccination, passive immunisation by administration of 
immunoglobulins, and chemoprophylaxis are specified as 
preventive measures. Information on post-exposure prophy-
laxis of specific infectious diseases can also be found in the 
“RKI-Guidebook for physicians” (“Ratgeber für Ärzte” des 
RKI; www.rki.de/ratgeber).
Diphtheria For persons in close (face to face) contact with cases. 
During epidemics or regionally increased morbidity.
Chemoprophylaxis:
Independent of vaccination status, preventive anti-
biotic treatment is recommended, e. g., with Erythro-
mycin (see RKI-Guidebook for physicians “diphtheria”, 
www.rki.de > Infektionskrankheiten A – Z > Diphtherie). 
Post-exposure vaccination is indicated if the most 
recent vaccination occurred > 5 years previously.
In accordance with the recommendations of the health 
authorities.




Chemoprophylaxis is recommended after close contact with a 
patient with invasive Haemophilus influenzae type b Infection:
 ▶ For all household members starting at age 1 month, if either 
an unimmunised or insufficiently immunised child aged up 
to 4 years or a person with a relevant immunodeficiency is 
present;




From 1 month of age: 20 mg/kg/day (up to a maximum 
of 600 mg) in 1 single dose for 4 days.
Adults: 600 mg p. o. in 1 single dose for 4 days.
As administration of rifampicin is contraindicated in 
pregnant women, ceftriaxone can be used for prophy-
laxis instead, if necessary.
If prophylaxis is indicated, it should be started as soon 
as possible, and at latest 7 days after the onset of 
disease in the index case.
Hepatitis A 
(HA)
Contact with hepatitis A patients (especially in community  
facilities).
Post-exposure vaccination:
Following exposure in persons for whom hepatitis A pre-
sents a particular danger (e. g., those chronically infec-
ted with HBV or HCV), an immunoglobulin preparation 
should be given simultaneously with the 1st vaccination. 
See also “Ratgeber Hepatitis A” [“Hepatitis A Guide“] at 
www.rki.de > Infektionskrankheiten A – Z > Hepatitis A.
Hepatitis B 
(HB)
Injuries from objects potentially containing HBV (e. g., a needle 
stick) or blood contact with mucosa or non-intact skin.
Newborn babies either of HBsAg positive mothers or of mothers 
with unknown HBsAg status (regardless of birth weight).
See post-exposure hepatitis B immune prophylaxis, 
p. 325.
See comments on the vaccination schedule, p. 311.
Measles People with unclear vaccination status, who have not been vac-
cinated, or who received only one vaccination during childhood 
after contact with measles cases.
 ▶ at the age of 6 to 8 months: exceptionally after individual risk 
benefit consideration (Off-label-use)
Vaccination with MMR(V)**vaccine preferably within 
3 days after exposition; according to the number of 
vaccine doses or the time of administration please 
consider the following age-specific recommendations. 
** MMR(V) = MMR with or without co-administration  
    of VZV vaccine 
1st vaccination;  
a 2nd and 3rd vaccination should be given at the age of  
11 to 14 and 15 to 23 months.
Vaccination against Indication Notes on use (Note package leaflet/ 
   Summary of Product Characteristics)
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Meningococci Chemoprophylaxis is recommended for persons in close 




 ▶ All household contact members,
 ▶ Persons in contact with a patient’s oropharyngeal secretions,
 ▶ Contact persons in children’s establishments with children 
under 6 years of age (only in the affected group in cases 
where the groups are well separated),
 ▶ Persons in close contact in community facilities with a 
household-like character (for example, boarding schools, 
hostels and barracks).
Chemoprophylaxis is indicated if close contact with the index 
patient took place in the 7 days preceding the onset of illness. 
Chemoprophylaxis should take place as soon as possible after 
diagnosis of the index patient; however, it is useful up to 10 days 
after the last exposure.
In addition to chemoprophylaxis, meningococcal vaccinati-
on of unvaccinated household contacts or close contacts of a 
household-like character is recommended if the infection of the 
index case was caused by serogroups A, C, W Y or B. The vacci-
nation should be given as soon as possible after contact.
Chemoprophylaxis:
Rifampicin:
Newborn babies:  
10 mg/kg/day in 2 single doses p. o. for 2 days
Infants, children and adolescents up to 60 kg:
20 mg/kg/day in 2 single doses p. o. for 2 days  
(maximum single dose 600 mg) 
Adolescents and adults from 60 kg:
2 × 600 mg/day for 2 days.
Eradication rate: 72 – 90 %
Or:
Ciprofloxacin:
From 18 years of age: 1 × 500 mg p. o.
Eradication rate: 90 – 95 %
Where applicable, Ceftriaxone:
Up to 12 years of age: 125 mg i. m.
From 12 years of age: 250 mg i. m. in 1 single dose
Eradication rate: 97 %
Because administration of rifampicin and gyrase  
inhibitors is contraindicated in pregnant women,  
ceftriaxone can be used as prophylaxis if necessary.
The index patient with an invasive meningococcal  
infection should also receive rifampicin after completion 
of therapy, unless he or she received intravenous  
treatment with a third-generation cephalosporin.
Post-exposure vaccination:
 ▶ For serogroup C: 
Vaccination with a conjugate vaccine from 2 months of 
age, according to the Summary of Product Characte-
ristics (see p. 312)
Vaccination against Indication Notes on use (Note package leaflet/ 




 ▶ at the age of von 9 to 10 months,
 ▶ at the age of 11 months to 17 years, 
 ▶ at the age of 18 years or more, born after 1970
1st vaccination; 
the 2nd vaccination should be given at the beginning 
of the 2nd year of life.
People with unclear vaccination status or who 
have not been vaccinated vaccination with 2 doses 
administered at least 4 weeks apart; People who 
have received only one vaccination receive 1 more 
vaccination.
People who have not been vaccinated, with unclear 
vaccination status, or who have been given only 
one vaccination during childhood receive 1 more 
vaccination. 
Passive immunisation with immunoglobulins can be 
considered up to 6 days after exposition particularly 
for unprotected people with contraindicated vaccina-
tion and a high risk of complications, like infants less 
than 6 months of age, immunodeficient individuals 
and pregnant women where necessary.
Infants between 6 to 8 months of age can receive 
immunoglobulins after individual risk-benefit consi-
deration alternatively to the 1st vaccination. 
After administration of immunoglobulins, the MMR 
vaccination is not reliably effective for 5 – 6 months. 
This should be taken into consideration in the event 
of an indication for immunoglobulin administration 
(see also Epid. Bull. 29/2001, S. 223). (www.rki.de > 
Infektionsschutz > Epidemiologisches Bulletin > issue 
29/2001.
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Tetanus See Table 5, p. 327.
Rabies See Table 6, p. 328.
Varicella 1. In non-immunised persons with no history of varicella and 
in contact with persons at increased risk.
2. Persons at increased risk of varicella complications, including:
 ▶ Non-immunised pregnant women with no history of varicella,
 ▶ Immunocompromised patients with uncertain or absent 
varicella immunity,
 ▶ Newborn babies whose mothers became ill with varicella 
between 5 days preceding and 2 days following delivery,
 ▶ Preterm-babies born in or after the 28th gestation week, whose 
mothers are not immune, if exposed in the neonatal period,
 ▶ Preterm babies born before the 28th gestation week if exposed 
in the neonatal period regardless of their mother’s immune 
status.
Post-exposure vaccination within 5 days of exposure* or 
within 3 days following commencement of the rash in 
the index case. Independent of these measures, contact 
with persons at risk (for example, those listed in point 2) 
should be avoided at all costs.
Post-exposure administration of varicella zoster immu-
noglobulin (VZIG) as soon as possible within 3 to 10 
days at maximum following exposure.* VZIG can prevent 
or markedly alleviate the outbreak of disease.
Please follow the Summary of Product Characteristics for 
the administration and dosing of VZIG!
Post-exposure prophylaxis with VZIG might be  
accomplished by use of antivirals.
* Exposure is defined as:
 ▶ 1 hour or longer with an infectious person in a room,
 ▶ Face to face contact,
 ▶ Household contact.
Mumps Non-immunised persons, persons immunised once during 
childhood, and persons with an unclear immune status in con-
tact with mumps cases, if possible within 3 days after exposure.
One-time vaccination with an MMR vaccine.
Pertussis Persons without vaccination protection in close contact in a 
family, shared accommodation, or a community facility.
Chemoprophylaxis with a macrolide is recommended 
(see also RKI-Ratgeber für Ärzte “Pertussis” [“Pertus-
sis Guide“] at www.rki.de > Infektionskrankheiten A – Z 
> Pertussis).
Vaccination against Indication Notes on use (Note package leaflet/ 
   Summary of Product Characteristics)
(Table 3 continued)
Poliomyelitis All contact persons of a poliomyelitis case regardless of their 
vaccination status. 
A secondary case is a cause for ring vaccinations.
Immediate post-exposure vaccination with IPV.
Immediate extensive investigations and stipulation of 
measures by the health authorities.
Ring vaccinations with IPV and stipulation of further 
measures by decree of health authorities.
Meningococci
(continued)
 ▶ For serogroups A, W or Y: 
Vaccination with a quadrivalent conjugate vaccine, if 
licensed for the respective age group (see p. 313).
 ▶ For serogroup B:
Vaccination with a MenB-vaccine, according to the 
Summary of Product Characteristics and if licensed for 
the respective age group (p. 312).
See also updates in Epid. Bull. 33/2010 and Epid. Bull. 
31/2012 (www.rki.de > Infektionsschutz > Epidemiologi-
sches Bulletin > issues 33/2010 and 31/2012).
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 ▶ A “meningococcal disease outbreak” is defined as 2 or 
more cases of the same serogroup within 4 weeks in a 
children’s facility, school class, playgroup, a community 
facility with a household-like character (for example, a 
hostel, boarding school, or barracks);
 ▶ A “regionally clustered occurrence” is defined as 3 or 
more cases of the same serogroup within 3 months 
• in a restricted age group of the population (e. g.,  
 adolescents) in one place, or 
• in a region with a resulting incidence ≥ 10/100,000 in 
 the respective population.
As a supplement to antibiotic prophylaxis for close contact 
persons (see Table 3, p. 323, as well as the recommenda-
tions of the German Society of Paediatric Infectiology 
[Deutsche Gesellschaft für Pädiatrische Infektiologie 
(DGPI)], of the National Reference Centre for Meningoco- 
cci, and the Ratgeber für Ärzte [Guide for Physicians] of the 
RKI), the responsible health authorities can additionally 
recommend vaccination prophylaxis if the clustered occur-
rence or the outbreak was caused by a strain preventable 
by vaccination. Vaccination prophylaxis is justified by the 
possibility of further cases occurring up to a few months 
after the onset of the first illnesses.
As with antibiotic prophylaxis, close contacts in the 
households of patients, their intimate partners, and close 
contacts in children’s facilities, school classes, playgroups, 
and community facilities with a household-like character 
can be included in prophylactic vaccination in the event of 
an outbreak.
In the case of a regionally clustered occurrence, the deci-
sion of the responsible health authorities must be made 
considering the epidemiological and temporal correlations 
of the diseases, their age distribution, the level of public 
concern, and the feasibility of the measures.
Authorised vaccines corresponding to the meningococcus 
serogroup causing the outbreak can be used for vaccinati-
on (see notes on use in Table 2 and, p. 312). 
Whenever meningococcal meningitis is suspected, materi-
al for isolation of the pathogen should immediately be sent 
to a suitable laboratory. The Public Health Department 
should urge that samples of isolated meningococci be dis-
patched as rapidly as possible to the National Reference 
Centre to ensure their detailed typing and to permit recom-
mending preventive vaccination in the event of a clustered 
occurrence.
5.2. Vaccinations for clustered occurrences or outbreaks of meningococcal diseases
5.3. Post-exposure hepatitis B immunoprophylaxis after exposure to HBV-containing material
Prompt prophylaxis is required in case of exposure to HBV. 
The following notes were compiled for application in the field 
of occupational health and can be transferred to other health 
service fields.
Lacerations and puncture wounds (especially with hollow 
needles) and blood contact with mucosa or broken skin pre-
sent a risk of infection. Any such event (for example, during 
patient care, the patient hereby called the “index patient”) 
should be reported as an occupational accident by the em-
ployee (hereby called the “exposed person”). The HBsAg 
status of the index patient and the HBV vaccination status 
of the exposed person should be determined.   
Further measures depend on the HBsAg status of the index 
patient:
1.  If the index patient is HBsAg negative: further measures 
 in regard to hepatitis B are superfluous (see *). If the 
 exposed person is not vaccinated or vaccination is incom- 
 plete, primary immunisation should be started and com- 
 pleted, respectively.
2. If the index patient is HBsAg positive: further measures 
 depend on the vaccination status of the exposed person 
 and are explained below.
3.  If the HBsAg status of the index patient is unknown: 
 the HBsAg level of the index patient should be determined 
 immediately (within 48 hours). Depending on the result of 
 the HBsAg testing intervention should proceed as descri- 
 bed in 1 or 2, above. If testing is not possible within 48 
 hours or is simply not possible (e. g., injury due to a 
 hollow needle in a trash bag), the index patient is classified 
 as HBsAg positive, and further measures depend on the 
 vaccination status of the exposed person (see **). 
The proceedings described in the following are additionally 
depicted in a flow chart (see Figure 1, p. 326).
For exposed persons with complete vaccination the  
following applies:
The measures to be taken depend on the most recent anti-
HBs level:
 ▶ Anti-HBs was determined within the last 10 years: 
– Anti-HBs was ≥ 100 IU/l: No action, 
–  Anti-HBs was 10 – 99 IU/l: Immediate determination 
 of the current anti-HBs level, with further action 
 depending on the test result (see Table 4, p. 327),
–  Anti-HBs was < 10 IU/l: Blood withdrawal (testing for 
 HBsAg, anti-HBc, and anti-HBs), succeeded by imme- 
 diate simultaneous administration of HB vaccine and HB 
 immunoglobulin (without waiting for the test results).**
 Exception: If at a prior point in time, i. e. more than 
 10 years ago, an anti-HBs ≥ 100 IU/l was recorded, only 
 HB vaccine (not HB immunoglobulin) should be given 
 (see the flow chart in Figure 1, p. 326).






































than 10 years 




Anti-HBs was < 10 IU/l
Anti-HBs was 10 – 99 IU/l
Anti-HBs was ≥ 100 IU/l
No
No
Current anti-HBs ≥ 100 IU/l
Current anti-HBs 10 – 99 IU/l
* In incompletely vaccinated or unvaccinated persons vaccination schedule should be completed.
Current  
anti-HBs < 10 IU/l
or testing not possible 
within 48 h 
 ▶ Last Anti-HBs testing was longer than 10 years ago or never 
(or if testing result is unknown): Immediate testing of the 
current anti-HBs level. Further action depends on the test 
result (see Table 4, p. 327).
For exposed persons with incomplete vaccination, the 
following applies:
 ▶ Immediate testing of the current anti-HBs level. Further 
action depends on the test result (see Table 4, p. 327).
 ▶ Administration of missing vaccinations (where appli-
cable, a shortened vaccination schedule can be used; see 
Summary of Product Characteristics). 
For unvaccinated exposed persons and known  
“non-responders” (individuals with permanent anti-HBs 
< 10IU/l) the following applies:
 ▶ Blood withdrawal (testing for HBsAg, anti-HBc, anti-
HBs), and subsequent immediate simultaneous admi-
nistration of HB vaccine and HB immunoglobulin (wit-
hout waiting for the test results).** 
 ▶ For unvaccinated persons, 2 additional vaccine doses 
(after the initial dose) should be given according to the 
standard vaccination schedule in order to achieve a 
complete primary immunisation. Antibody response 
following HB vaccination is not affected by simultane-
ous administration of immunoglobulin. 
* Very rarely, HBsAg-negative persons can be infectious. From a cost-benefit point of view, routine testing for HBV-DNA of all index patients is not practicable.
** An isolated positive result of an anti-HBc test necessitates further diagnostic clarification. However, required vaccination should not be delayed.
Figure 1: Procedure for the hepatitis B immunoprophylaxis (see detailed information, p. 325)
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Current anti-HBs level Required administration of 
HB vaccine HB immunoglobulin
≥ 100 IU/l no no
10 – 99 IU/l yes no
< 10 IU/l or not determinable 
within 48 hours 
and anti-HBs was ≥ 100 IE/l at a prior point in time yes no
and anti-HBs was never ≥ 100 IE/l, or is unknown yes yes
Table 4: Hepatitis B immunoprophylaxis after exposure depending on the current anti-HBs level  
 (see also flow chart, Figure 1!)
Previous history of tetanus immunisation Clean, negligible wounds All other wounds 1 
(of tetanus vaccine doses received) DTaP/Tdap 2 TIG 3 DTaP/Tdap 2 TIG 3
Unknown Yes No Yes Yes
1 Yes No Yes Yes
2 Yes No Yes No 4 
3 or more No 5 No No 5 No 6
5.4. Post-exposure tetanus immunoprophylaxis in case of injury
Table 5: Tetanus immunoprophylaxis in case of injury
1  This includes wounds that are deep and/or soiled (contaminated with 
dust, earth, sputum, or stool), and injuries with tissue fragmentati-
on and reduced oxygen supply or penetration of foreign bodies (e. g., 
contused, lacerated, bite, puncture, or gunshot wounds). Further indi-
cations include:
 ▶ Severe burns and frostbite
 ▶ Tissue necrosis
 ▶ Septic miscarriages 
2  Children under 6 years old receive a combination vaccine with DTaP, 
while older children receive Tdap (that is, a tetanus and diphtheria vac-
cine with a reduced diphtheria toxoid content and reduced acellular 
pertussis component). Adults also receive Tdap if they have not yet 
received a Tdap vaccine as adults (≥ 18 years of age) or if there is a 
current indication for pertussis vaccination (see Table 2, p. 308). 
3  TIG = Tetanus immunoglobulin. Generally, 250 IU are used; TIG is ad-
ministered simultaneously with a DTaP/Tdap vaccine in contralateral 
parts of the body. The dose can be increased to 500 IU in cases of 
infected wounds (that do not receive adequate surgical treatment 
within 24 hours); deep or contaminated wounds with tissue damage 
and reduced oxygen supply as well as foreign body penetration (e. g. 
bites, stab or bullet wounds); severe burns and frostbite, tissue necro-
sis and septic abortions. 
4 Yes if the injury dates back longer than 24 hours.
5  Yes (1 dose), if more than 5 years have passed since the last vaccination
6  Yes (1 dose), if more than 10 years have passed since the last vaccina-
tion.
Even trivial injuries can be entry ports for tetanus bacteria or spores. In the event of an injury, the treating physici-
an should verify the current tetanus vaccination status. Tetanus immunoprophylaxis must be carried out immediately. 
Missed primary immunisation vaccinations must be reinstated in accordance with the recommendations given for 
primary immunisation
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5.5. Post-exposure rabies immunoprophylaxis
Detailed information on the epidemiology of rabies in Germany can be found in Epid. Bull. 8/2011  







from a rabies vaccine bait
Touching of vaccine baits with intact skin.
Contact with the vaccination fluid of a  
damaged vaccine bait with broken skin.
Contamination of mucous membranes and 
fresh skin injuries with the vaccination fluid of a 
damaged vaccine bait.
Immunoprophylaxis *




Protective rabies vaccination and 
a single administration of rabies 
immunoglobulin (20 IU/kg body 
weight) simultaneously with the 
1st dose.
Type of exposure
from a wild animal, pet, or bat with suspected 
or confirmed rabies
Touching/feeding of animals;
licking of intact skin.
Superficial scratches or abrasions without blee-
ding; Licking or nibbling of broken skin. 
Bites or scratches;
Sputum contact with mucous membranes or 
wounds (e. g., through licking);
Suspected bite or scratch from a bat or mucous 
membrane contact with a bat.
Table 6: Post-exposure rabies immunoprophylaxis
* Individual vaccinations and administration of rabies immunoglobulin must be carefully documented.
Notes on post-exposure rabies immunoprophylaxis
 ▶ Potentially contaminated body sites and all wounds 
must be cleaned immediately and generously with soap 
or detergent, rinsed thoroughly with water, and treated 
with 70 % alcohol or an iodine preparation; this also 
applies to contamination with vaccination liquid from 
vaccine bait. When possible, wounds should not under-
go primary suturing.
 ▶ With exposure level II, a rabies vaccine is used for 
active immunisation according to the Summary of 
Products Characteristics.
 ▶ With exposure level III, in addition to active immunisati-
on, passive immunisation with rabies immunoglobulin 
is initiated. As much rabies immunoglobulin as possible 
is instilled in and around the wound, and the remaining 
amount is administered intramuscularly. 
 ▶ If an indicated administration of rabies immunoglobu-
lin was not administered at first vaccination, it can still 
be given until 7 days after the first dose of rabies vaccine.
 ▶ If a person who was previously vaccinated with rabies 
cell culture vaccines is newly exposed, the Summary of 
Product Characteristics must be followed.
 ▶ If the vaccination history shows either incomplete vacci-
nation or vaccination with vaccines not authorised in the 
EU, full immunoprophylaxis is carried out in accordance 
with Table 6.
 ▶ If indicated, immunoprophylaxis must be carried out 
immediately; there should be no delay while waiting for 
clarification of a suspected infection in the biting animal. 
If the suspicion of rabies in the animal is not confirmed 
by veterinary examination, immunoprophylaxis can be 
discontinued or continued as pre-exposure vaccination.
 ▶ Care must be taken to check tetanus vaccination docu-
mentation and if necessary to administer simultaneous 
tetanus immunoprophylaxis (see Table 5, p. 327).
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6.  Recommendations for catch-up vaccinations 
 For children, adolescents and adults with incomplete or unknown vaccination status
6.1. Preliminary remarks
The present notes are based on the recommendations for 
routine vaccination of infants, children, adolescents and 
adults (see immunisation schedule, p. 303).
These notes are intended to guide physicians in deci-
ding which vaccinations are required for unvaccinated, 
delayed, or incompletely vaccinated individuals to achieve the 
recommended vaccination protection according to age. 
Evidence supporting this guidance is often limited, as stu-
dies of high methodological quality examining vaccine ef-
fectiveness under irregular immunisation schedules are 
often not available. The recommendations given here are 
therefore mainly based on the long-term experience and 
expertise of STIKO members. 
In addition, expert opinions and the recommendations 
of other international immunisation technical advisory 
groups were considered.1,2,6-11 Bibliographic details for the 
following references are listed at the end of the chapter on 
“recommendations for catch-up vaccinations”.
Every physician consultation of children, adolescents and 
adults should be used to check the individual’s vaccination 
status and to prompt catch-up of missing vaccinations.
6.2.  Unvaccinated persons and persons with unclear  
 vaccination status
An overview regarding recommended catch-up vaccina-
tions and the corresponding immunisation schedule for 
different age groups is given in Table 7 (see p. 330 – 332). 
Age groups were chosen to incorporate age-related parti-
cularities in vaccination recommendations and application 
notes according to the Summary of Product Characteristics 
of licensed vaccines. The relevant age for the required vacci-
nations is the age at start of the catch-up series.
6.3. Partly immunised persons
For partly immunised children, adolescents, and adults, 
all documented vaccinations up to the present are coun-
ted, if the interval between single doses was not shorter 
than the recommended minimum interval. For long- 
lasting vaccination protection, it is especially impor-
tant that the recommended minimum interval between 
second-to-last and last vaccinations (6 months for most 
vaccines) is not shortened during primary or basic immu-
nisation (P). Given this prerequisite, the following applies:
Every vaccination counts!
This means that there are, in principle, no illegitimately 
long intervals between vaccinations. Usually, a primary im-
munisation series that has been interrupted for many years 
– for example, against diphtheria, TBE, tetanus, poliomyeli-
tis, or hepatitis B – does not have to be repeated. A booster 
vaccination that has not been administered according to 
schedule can also be administered at a later point in time.
In considering the number and timing of previously ad-
ministered vaccines, an individual immunisation schedu-
le should be compiled. The number of vaccine doses nee-
ded to complete the interrupted primary immunisation 
series is, in principle, calculated based on the recommen-
dations for the age at which the vaccination series was 
started. For vaccinations that are recommended only until 
a specific age (pneumococcal for infants/children, Hib, 
rotavirus), an interrupted primary immunisation series 
will not be continued if the vaccinee has in the meantime 
surpassed this specific age.
An incomplete HPV vaccination series, however, should 
be completed even after the age of 18 (clarify who will bear 
the cost).
Literature: see p. 337.
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Table 7:  Recommended catch-up vaccinations among children, adolescents and adults with missing primary  
 immunisation (P)
Children < 12 months
Vaccination 
against
Minimum interval in months after previous vaccination dose Age in years
0 1 1 6 5 – 8 9 – 17
Tetanus C1 C2 C3 C4 B1 B2
Diphtheria (D) C1 C2 C3 C4 B1 B2
Pertussis (aP) C1 C2 C3 C4 B1 B2
Hib C1 C2a C3 C4
Poliomyelitis C1 C2a C3 C4 B1
Hepatitis B C1 C2a C3 C4
Pneumococcus C1 C2 C3
Unvaccinated persons:  Apply the table using the patient’s current age
Partly immunised persons: Apply table using the patient’s age when first vaccinated with the respective antigen
C = Catch-up vaccination B = Booster vaccination  P = Primary vaccination
Footnotes at the end of table 7
Children aged 12 months to < 5 years
Vaccination 
against
Minimum interval in months after previous vaccination dose Age in years
0 1 6 5 – 17
Tetanus C1 C2 C3 B1b B2b
Diphtheria (D) C1 C2 C3 B1b B2b
Pertussis (aP) C1 C2 C3 B1b B2b
Hib C1
Poliomyelitis C1 C2 C3 B1c
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Children from 5 to < 11 years
Vaccination
against
Minimum interval in months after previous vaccination dose Age in years
0 1 6 10 – 17
Tetanus C1 C2 C3 B1f
Diphtheria (d) C1 C2 C3 B1f
Pertussis (ap)g C1 C2 C3 B1f
Poliomyelitis C1 C2 C3 B1




HPV (Girls) from the 
age of 9 years
P1 P2
(Table 7 continued)
Children/adolescents from 11 to < 18 years
Vaccination
against
Minimum interval in months after previous vaccination dose Vaccination interval
0 1 6 5 – 10 years
Tetanus C1 C2 C3 B1
Diphtheria (d) C1 C2 C3 B1
Pertussis (ap)g C1 B1
Poliomyelitis C1 C2 C3 B1






9 – 14 years P1 P2
> 14 years C1 C2 C3
At the age of 9 – 13 years or 9 – 14 years (depending on product), HPV  
primary immunisation (P) consists of 2 doses 6 months apart. For 
catch-up vaccinations (C) and completion of vaccination series at age 
> 13 years and > 14 years, respectively, 3 doses are necessary  
(note Summary of Product Characteristics).
Footnotes at the end of table 7
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(Table 7 continued)
Adults over 18 years
Vaccination
against
Minimum interval in months after previous vaccination dose Vaccination interval
0 1 6 Every 10 years
Tetanus C1 C2 C3 B
Diphtheria (d) C1 C2 C3 B
Pertussis (ap)g C1 B1 (one-time)
Poliomyelitis C1 C2 C3 B1 (one-time)
Measles for persons 
born after 1970
C1
Rubella for women 
in childbearing ageh 
C1 C2
Varicella for serone-
gative women who 
wish to conceive 
C1 C2
Pneumococcal  
for adults  
≥ 60 years of age
C1
Repeat immunisation only per individual 
indication, see Table 2, p. 308 
(after 6 years at the earliest)
According to the Recommendations of Routine Vaccinations (Effective: August 2016)
Hib = Haemophilus influenzae Typ b  MMR = Measles, mumps, rubella   HPV = Human papilloma virus
a) This dose can be omitted when using a monovalent vaccine.
b) Booster vaccination 5 – 10 years after the last dose of the primary immunisation, or after a previous booster vaccination. 
c) The booster vaccination should be administered at the age of 9 – 17 years.
d) The pneumococcal vaccination is not recommended as a routine vaccination after the age of 24 months; accordingly, there is 
 no need for catch-up vaccination.
e) Starting at the age of 11 months.
f) Depending on the age at completion of the primary immunisation, 2 booster vaccinations may be appropriate before adulthood; 
 the interval between P and B1 and between B1 and B2 is 5 – 10 years. 
g) As there is no monovalent pertussis vaccine available in Germany, only Tdap or Tdap-IPV combination vaccines can be used. 
h) Unvaccinated women or women without documented vaccinations are administered 2 doses, while one-time vaccinated women 
 are administered 1 dose. In absence of a monovalent rubella vaccine, an MMR vaccine can be used. 
A 2.5-year-old child received one dose each of the hexavalent vaccine 
DTaP-IPV-Hib-HepB and the pneumococcal vaccine at 2 and 3 months; 
after this point, no further vaccinations were given.
The completion of this primary immunisation is carried out according to 
the information for “Children aged < 12 months” (= age at first adminis-
tered vaccination) in Table 7. Two more vaccinations are required against 
tetanus, diphtheria, pertussis, poliomyelitis and hepatitis B, separated by 
an interval of at least 6 months. One additional dose of a Hib-containing 
vaccine would be sufficient for protection against Haemophilus influenzae 
type b, as only 1 dose is needed after the age of 12 months. However, 
both vaccinations can be carried out with a hexavalent vaccine to keep 
the number of injections to a minimum. The additional dose of Hib is 
not likely to pose an increased risk of side effects.
The missing vaccinations against MMR, varicella, and meningococcal C 
have to be administered according to the information for “Children aged 
from 12 months to < 5 years” (because at this time the child is unvacci-
nated against these diseases). The primary immunisation against pneu-
mococci will not be initiated because this vaccination is not recommen-
ded after the age of 24 months (except for children with certain underly-
ing diseases, in which case 2 additional doses would be required at an 
interval of at least 8 weeks). 
Example
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6.4.  Procedure in the case of missing immunisation  
 documentation
If the vaccination card is not traceable or lost, medical files 
should be used to identify previously administered vacci-
nations. Where appropriate, a new vaccination card can be 
issued based on the documented history of vaccinations.
Missing vaccination cards is a frequent problem in daily 
life among migrant children, adolescents, and adults. A 
summary of up to date vaccination recommendations ac-
cording to country of origin can be found on the webpages 
of the WHO (http://apps.who.int/immunization_monito-
ring/globalsummary/schedules) and ECDC (http://vaccine-
schedule.ecdc.europa.eu/Pages/Scheduler.aspx) listing all 
national immunisation schedules. In principle, however, 
according to STIKO recommendations, all vaccinations 
that are not documented should be administered under the 
assumption that they are missing.
In case of an unknown vaccination status, including mis-
sing or incomplete documentation of vaccinations, it 
should be assumed in the interest of the individual to be 
protected that the respective vaccinations are missing. 
Anamnestic information on vaccination or disease history 
(including measles, mumps and rubella) is, with the excep-
tion of varicella, often unreliable and should not be incorpo-
rated into the planning of catch-up vaccinations. Deviations 
from this principle might be justifiable in individual cases.
6.5. Anamnestic information regarding varicella
Varicella (chicken pox) is an exception regarding the re-
liability of anamnestic information. Studies show that 
such information showing a previous history of varicella 
with typical clinical manifestations is of high validity.3 A 
varicella vaccination is not required after an anamnestic 
response indicating prior varicella disease. If in doubt, a 
varicella vaccination should be administered, especially 
because varicella complications (including pneumonia, 
encephalitis, and the risk of fetopathy if contracted du-
ring pregnancy) increase among adolescents and young 
adults.4 It should be noted that adolescents and young 
adults coming from tropical countries, especially Sou-
theast Asia, are less frequently immune to varicella than 
individuals in Europe.
6.6. Indication for serological testing
Serological testing to determine the need for catch-up 
vaccinations based on antibody titres only makes sense in 
exceptional cases, because the test methods used in clini-
cal laboratories often do not have a sufficient sensitivity 
and specificity. For some vaccine-preventable diseases 
(e. g., pertussis), no reliable serological correlate exists that 
would be suitable as a surrogate marker for the presence of 
immunity. Moreover, antibody titre levels do not allow dra-
wing conclusions regarding potential cellular immunity. 
In principle, routine antibody testing is not appropriate 
before or after routine vaccinations. Exceptions are 
verifying vaccination success in patients with immuno-
deficiency (see STIKO notes in Epid. Bull. 39/2005, (www.
rki.de > Infektionsschutz > Epidemiologisches Bulletin > 
issue 39/2005), and confirming protection against hepatitis 
B among persons with an elevated exposure risk (see Table 
2, p. 305). Serological testing is also recommended to con-
firm protection against varicella among women who wish 
to conceive and who have unclear anamnesis of varicella.
6.7. Are “too many” vaccinations dangerous?
In general, there is no elevated risk of side effects resulting 
from excess vaccine doses. To limit necessary injections, it 
is therefore possible to use combination vaccines even if 
not all antigens/vaccine components are needed (see also 
‘Choice of vaccines’, below). On rare occasions, the repea-
ted administration of inactivated vaccines can cause adverse 
events such as pronounced local reactions including pain-
ful swelling and reddening of the affected extremity (called 
the ‘Arthus reaction’). The self-limiting reaction most likely 
occurs after very frequent vaccination with tetanus and/or 
diphtheria toxoid. In this case, antibody testing should be 
conducted before the administration of further Td vaccines. 
This risk does not exist for pertussis antigens.5
6.8. Choice of vaccines
Combination vaccines are to be preferred over monova-
lent vaccines if in consequence the number of injections 
can be reduced, the vaccination goal can be reached at an 
earlier date, and vaccination acceptance can be increased. 
There are at present no monovalent vaccines in Germany 
available against certain diseases (childhood diphtheria, 
measles, mumps, rubella, and pertussis); in these cases it 
is unavoidable to administer combination vaccines (for ex-
ample, to catch-up a missing mumps or rubella vaccination 
with an MMR vaccine). Individual immunisation schedules 
are often necessary owing to age-dependent changes of vac-
cination indications (for example, vaccination for Haemophi-
lus influenzae type b until the 5th birthday, and pneumococci 
until the 2nd birthday) and the restriction of licensed vaccine 
administration to certain age groups.
According to the current Summary of Product Characteris-
tics, the hexavalent vaccines Infanrix hexa® (DTaP-IPV-HiB-
HepB) and Hexyon® can be used for basic immunisation 
and booster vaccinations for infants and small children; a 
concrete age limit is not given. According to the Paul Ehr-
lich Institute in its function as national regulatory authori-
ty, in this context there is no binding definition of the term 
“small child”. According to the current Summary of Product 
Characteristics, the pentavalent vaccines Infanrix®-IPV+Hib 
(DTaP-IPV-Hib) and Pentavac® are suitable from the age of 
2 months; an upper age limit is not given (see Table 8, p. 
336). For basic immunisation against Haemophilus influenzae 
Type b, a single dose of vaccine from 12 months is sufficient. 
Nonetheless, the usual pentavalent or hexavalent vaccines 
DTaP-IPV-Hib(-HepB) can continue to be administered if 
this is necessary to complete the other vaccinations. Negative 
effects due to excess Hib vaccine doses are not to be expected.
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Alternatively, missing vaccinations can be completed with the 
tetravalent vaccine Infanrix® (DTaP, licensed until the 6th 
birthday) and, simultaneously or sequentially, with monova-
lent vaccines against hepatitis B and poliomyelitis. A vacci-
nation series started with a specific combination vaccine can 
be completed using vaccines from a different manufacturer.
Depending on age, differently dosed vaccines are used for 
hepatitis B vaccination (for more details see the Summary of 
Product Characteristics).
6.9. Vaccinations against tetanus, diphtheria,  
 poliomyelitis and pertussis from the age of 5 – 6 years
In older children and adults, protection against pertussis 
can be achieved with a single dose of a combination vaccine 
including the pertussis component, because the vaccinee 
is usually not immunologically naïve against pertussis gi-
ven the current prevalence of Bordetella pertussis. A study 
showed that one vaccine dose induced an immunological 
response in more than 90 % of vaccinated individuals aged 
11 years and older.2 Equivalent information can also be 
found in the Summary of Product Characteristics for the 
respective vaccines.
Starting at the age of 5 to 6, vaccines with reduced antigen 
content (d instead of D and ap instead of aP) should be used 
for vaccinations against diphtheria and pertussis. Whilst 
the Td vaccines (Td-Impfstoff Mérieux®, Td-pur®, Td-Rix®, 
with the exception of Td-Immun®) and the monovalent IPV 
vaccine (IPV-Mérieux®) are licensed for primary immunisa-
tions according to the Summary of Product Characteristics, 
the combination vaccines with pertussis components (Tdap: 
(Boostrix®, Covaxis® [probably not available until 2017], 
TdaP-Immun®), Tdap-IPV: (Boostrix-Polio®, Repevax®)) 
are mainly intended for booster vaccinations.  
According to PEI, the term “primary immunisation” me-
rely refers to the first-time immunisation during infancy 
and early childhood, for which vaccines with higher anti-
gen content (upper case D and P) should be used. In its 
function as the national regulatory authority for vaccines in 
Germany, PEI determined that the above-mentioned ap-
containing vaccines can be used for the first-time immu-
nisation of older children, adolescents and adults whose 
vaccination status is unknown or who have not been previ-
ously vaccinated against Tdap-(IPV).
The use of the vaccines given below is covered by licensing 
in the respective age groups:
 
1. TdaP-IMMUN® (Tdap) vaccine for the primary immuni-
sation of individuals from the age of 4;
2. Boostrix® (Tdap), Boostrix-Polio® (Tdap-IPV), Covaxis® 
(Tdap) und Repevax® (Tdap-IPV) vaccines for primary 
immunisation from the age of ≥ 12 years.
Only when these vaccines are used outside the respective age 
groups, information about an off-label use should be pro-
vided (see p. 316 for off-label use), and this should also be 
documented in writing.
For booster vaccinations, all the vaccines named can be 
used without restrictions for the age stated in the respective 
licence. This includes the completion of previously initiated 
vaccination series.  
STIKO has published information on the “Use of Tdap 
and Tdap-IPV vaccines for the primary vaccination of indi-
viduals” in a statement in Epid. Bull. 4/2016 (www.rki.de > 
Infektionsschutz > Epidemiologisches Bulletin > issue 4/2016). 
6.10. Age-dependent recommendations for conducting 
 catch-up vaccinations
Age <12 months 
Missing DTaP-IPV-HepB-Hib and pneumococcal conju-
gate vaccine doses should be administered. To comple-
te primary immunization against DTaP-IPV-Hib-HepB, 
3 vaccine doses should be given at 1 month intervals and 
a 4th dose after an interval of ≥ 6 months since the previ-
ous vaccination. For full protection against pneumococcal 
disease 2 primary vaccine doses with a minimum interval 
of 2 months in between are required, which should be 
followed by a 3rd dose (booster) with a minimum interval 
of 6 months after the second dose. 
There is only a short time slot for catch-up of the rota- 
virus immunisation series, because administration of the 
1st dose should take place before the age of 12 weeks and 
the last dose preferably before the ages of 16 weeks (Rota-
rix®) or 20 – 22 weeks (RotaTeq®) depending to the used 
vaccine brand (see Summary of Product Characteristics). 
The vaccination series must be completed by the age of 24 
(Rotarix®) and 32 (RotaTeq®) weeks, respectively. 
Additional vaccinations are carried out according to the ge-
neral STIKO immunisation schedule.
Age 12 months to <5 years
Missing DTaP-IPV-HepB-Hib vaccine doses can be 
administered. For a complete primary immunisation, 2 
vaccine doses should be given at an interval of at least 
1 month, plus a 3rd vaccination after an interval of ≥ 6 
months since the previous vaccination. Booster vaccina-
tions are given at the age of 5 – 6 years (at earliest 2 ye-
ars after the 3rd dose) and at the age of 9 – 17 years. From 
the age of 12 months, Hib only requires 1 vaccine dose, 
and pneumococci only 2 vaccine doses at an interval of 
8 weeks. From the age of 2, a pneumococcal vaccination 
is only recommended for children in a risk category (in-
dication vaccination). Furthermore, 2 MMR and varicella 
vaccinations should be given at intervals of 4 – 6 weeks 
as well as a meningococcal C conjugate vaccination. Due 
to a slightly increased risk of febrile convulsions after 
the first MMRV combination vaccine dose in compari-
son with the simultaneous administration of the MMR 
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vaccine and the V vaccine, preference should be given to 
separate MMR and V vaccines for the first dose in child-
ren aged < 5 years. For the 2nd vaccination against MMR 
and V, either the MMRV combination vaccine or separate 
MMR and V vaccines can be used. 
Age 5 to <11 years 
Missing polio vaccinations and DTaP or Tdap vaccine doses 
should be administered using vaccines with an antigen con-
tent appropriate for age. Until the 6th birthday, according to 
the Summary of Product Characteristics it is possible to ad-
minister the tetravalent vaccine Infanrix® (DTaP) and simul-
taneously inject an IPV vaccination against polio (requiring 
2 or 3 doses depending on the manufacturer; see Summary 
of Product Characteristics) into the other arm.
From the age of 5 or 6 years (depending on the Summary of 
Product Characteristics), a vaccine with a reduced concentra-
tion of diphtheria toxoid (d) and pertussis antigen (p) should 
be given. If applicable, the combination vaccines Tdap or 
Tdap-IPV can be used (3 doses at intervals 0–1–6 months; 
see p. 334). Depending on age upon completion of the pri-
mary immunisation series, it might be appropriate for this 
age group to receive 1 or 2 Tdap booster vaccinations between 
the ages of 10 and 17 years. A booster vaccination should be 
given at the earliest 5 years after the last dose of the primary 
immunisation or the previous booster vaccination. Primary 
immunisation against hepatitis B consists of 3 vaccinations 
(0–1–6 months). In addition, 2 MMR and varicella vaccina-
tions are given at an interval of 4 to 6 weeks and one conju-
gate vaccine against meningococcal C.
Girls at the age of 9 – 13 and 14 years, respectively (product-
dependent), should receive 2 HPV vaccinations following 
the immunisation scheme reported in the Summary of 
Product Characteristics
Age 11 to <18 years
In case of a missing vaccination against pertussis, pro-
tection can be achieved with 1 dose of a Tdap or Tdap-IPV 
vaccine.12 If primary immunisation against tetanus, diph-
theria and poliomyelitis is also indicated, the first of the 
required 3 vaccinations (0–1–6 months) should be conduc-
ted with a Tdap or Tdap-IPV vaccine (see p. 334 and Table 8). 
A booster vaccination with Tdap or Tdap-IPV should be 
administered 5 to 10 years after completion of the primary 
immunisation series and if possible before reaching adult-
hood. Primary immunisation against hepatitis B should 
be conducted with 3 vaccine doses (0–1–6 months) using 
the vaccine licensed for the respective age. In addition, 2 
MMR and varicella vaccinations are to be given at an inter-
val of 4 to 6 weeks, and one conjugate vaccination against 
meningococcal C. 
Girls under the ages of 13 or 14 years (product-dependent) 
should receive a 2-dose HPV vaccination according to the 
vaccination scheme described in the Summary of Product 
Characteristics. Catch-up vaccinations should be offered 
to older girls and young women until the age of 17 years. 
For catch-up vaccinations when the primary vaccination 
was administered at the age of > 13 and > 14 years, respec-
tively, 3 doses are necessary (note the Summary of Product 
Characteristics).
Catch-up vaccinations in adulthood 
Adults should receive all vaccinations recommended for 
their respective age group, including catch-up vaccinations 
for tetanus, diphtheria, pertussis and poliomyelitis if ne-
cessary. Unvaccinated persons or persons with unknown 
vaccination status can receive 3 vaccination doses of a Td or 
Td-IPV combination vaccine (see p. 334; 0–1–6 months). To 
achieve a protection against pertussis, the first vaccination 
should be given as a Tdap or Tdap-IPV combination vacci-
ne (see p. 334).7 Td booster vaccinations should be admi-
nistered in all cases 10 years after the previous vaccination. 
For the first booster, a Tdap combination vaccine should be 
used once.
Persons born after 1970 of ≥ 18 years of age should receive 
a one-time measles-virus containing vaccine, preferably an 
MMR vaccine. Women of childbearing age should be given 
2 rubella vaccinations with an MMR vaccine. Varicella vacci-
nation (2 doses at an interval of 4–6 weeks) is recommended 
for seronegative women planning pregnancy. 
From the age of 60 years, STIKO recommends a one-time 
vaccination against pneumococcal disease with a polysaccha-
ride vaccine (PPSV23) and yearly vaccination against seaso-
nal influenza as routine vaccinations. A repeat vaccination 
against pneumococci should be given no sooner than 6 years 
later and should be determined on a case-by-case basis (see 
p. 313 and Table 2, p. 308).
See p. 337 for references and Table 8 regarding the section “Recommenda-
tions for catch-up vaccinations”.
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Antigen Brand name Minimum age  a Maximum age a 
DTaP Infanrix® 2 months 6th birthday (72 months)
DTaP-IPV-Hib Infanrix-IPV + Hib® 2 months No information
Pentavac® 2 months No information
DTaP-IPV-HepB-Hib Infanrix hexa® No information Including small children c
Hexyon® 6 weeks Including small children c
Td Td-pur® 5th birthday (60 months) f no age limit
Td-Immun® 5th birthday (60 months) no age limit
Td-Mérieux® 5th birthday (60 months) f no age limit
Td-Rix® 6th birthday (72 months) f no age limit
Tdap
Boostrix® 4th birthday (48 months) d no age limit
Covaxis® (currently not on the market, expected to 
be available again from 2017 on)
4th birthday (48 months) d no age limit
TdaP-IMMUN® 4th birthday (48 months) e no age limit
Tdap-IPV Boostrix Polio® 4th birthday (48 months) d no age limit
Repevax® 3rd birthday (36 months) d no age limit
Td-IPV Revaxis® 5th birthday (60 months) no age limit
IPV IPV-Mérieux® 2 months f no age limit
MMR M-M-RVaxPro® (9 –) 12 months b no age limit
Priorix® 9 months no age limit
MMR-V Priorix-Tetra® (9 –) 11 months  b 13th birthday
Varicella Varivax® (9 –) 12 months no age limit
Varilrix® (9 –) 11 months no age limit
Table 8:  Brand names and indicated age groups of vaccines available in Germany mentioned in the text
  (list does not claim to be exhaustive)
a  See also Summary of Product Characteristics (as of August 2016)
b If immunisation protection is considered necessary at an earlier point in time, vaccination can be given starting at the age of 9 months; 
 see recommendations for measles, mumps, and rubella (p. 312).
c  The Summary of Product Characteristics states that the vaccine can be used to vaccinate “infants and small children”. According to the licensing 
 authority, there is no binding definition of the term “small child”.
d  Primary immunisation of individuals from youth (12 years of age) whose vaccination status is unknown or who have not so far been vaccinated 
 complies with licensing. 
e  Primary immunisation of individuals from the age of 4 years whose vaccination status is unknown or who have not so far been vaccinated complies 
 with licensing. N. B. Notwithstanding the upper case “P” in the name of the compound, TdaP-IMMUN® is one of the pertussis vaccines with reduced 
 antigen content (ap).
f  Also licensed for primary and first-time immunisation.
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Cholera:
 1. Änderung der Empfehlungen zur Impfung gegen Cholera;  
(www.rki.de/epidbull issue 31/2010)
Yellow Fever:
 2. Wissenschaftliche Begründung zur Änderung der Gelbfieber-Impfemp-
fehlung aufgrund der Änderungen in den Regelungen der Internationalen 
Gesundheitsvorschriften zu Gelbfieber (ww.rki.de/epidbull issue 35/2015) 
Hepatitis B:
 3. Wissenschaftliche Begründung für die Änderung der Empfehlung zur 
Impfung gegen Hepatitis B (www.rki.de/epidbull issue 36/37/2013)
 4. Hinweise zur Notwendigkeit der Wiederimpfung 10 Jahre nach erfolgter 
Grundimmunisierung gegen Hepatitis B (HB) im Säuglings- bzw. Kindes-
alter (www.rki.de/epidbull issue 31/2007)
HPV:
 5. Wissenschaftliche Begründung für die Änderung der Empfehlung zur Imp-
fung gegen humane Papillomviren (www.rki.de/epidbull issue 35/2014)
 6. Impfung gegen HPV – Aktuelle Bewertung der STIKO 
(www.rki.de/epidbull issue 32/2009)
 7. Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 
Jahren – Empfehlung und Begründung 
(www.rki.de/epidbull issue 12/2007)
Seasonal Influenza:
8. Wissenschaftliche Begründung für die Änderung der Empfehlung zur 
Impfung gegen Influenza 
(www.rki.de/epidbull issue 36/37/2013)
9. Änderung der Empfehlungen zur Impfung gegen Influenza; Empfehlung 
zur Impfung von Schwangeren (www.rki.de/epidbull issue 31/2010)
10. Begründung der STIKO für die Influenza-Impfung bei Patienten mit Multi-
pler Sklerose (MS) mit durch Infektionen getriggerten Schüben  
(www.rki.de/epidbull issue 32/2004)
11. Wirksamkeit und Sicherheit der Influenza-Impfung für Patienten mit 
chronischen Lungenerkrankungen  
(online verfügbar unter: www.rki.de > Kommissionen > STIKO > Empfeh-
lung der STIKO > Begründung > Influenza)
Measles:
12. Änderung der Empfehlung zur Impfung gegen Masern 
(www.rki.de/epidbull issue 32/2010)
Meningococcal: 
13. Aktualisierung der Meningokokken-Impfempfehlung: Indikationsimp-
fung – Postexpositionelle Impfung – Berufliche Indikation;  
(www.rki.de/epidbull issue 37/2015)
14. Änderung der Empfehlungen zur Indikationsimpfung gegen Meningokok-
ken (www.rki.de/epidbull issue 32/2012)
15. Änderung der Empfehlungen zur Impfung gegen Meningokokken;  
(www.rki.de/epidbull issue 32/2010)
16. Empfehlung und Begründung einer postexpositionellen Meningokokken-
Impfung (www.rki.de/epidbull issue 31/2009)
17. Begründungen zur allgemeinen Empfehlung der Impfung gegen  
Meningokokken im Säuglings- und Kindesalter – Impfung der Kinder 
im 2. Lebensjahr mit konjugiertem Meningokokken-Impfstoff der Sero-
gruppe C (www.rki.de/epidbull issue 31/2006) 
 
Mumps: 
18. Änderung der Empfehlung zur Impfung gegen Mumps;  
(www.rki.de/epidbull issue 31/2012)
Pertussis: 
19. Zusätzliche Pertussis-Impfung im Erwachsenenalter als Tdap-Kombina-
tionsimpfung bei der nächsten fälligen Td-Impfung – Empfehlung und 
Begründung (www.rki.de/epidbull issue 31/2009)
20. Klinische Studien mit azellulären Pertussiskomponenten-Impfstoffen bei 
Erwachsenen (www.rki.de/epidbull issue 31/2009)
21. Erweiterung der beruflichen Indikationen für eine Pertussis-Impfung; /
(www.rki.de/epidbull issue 31/2009)
22. Begründung für die STIKO-Empfehlung einer Pertussis-Auffrischimpfung 
im Vorschulalter (www.rki.de/epidbull issue 3/2006) 
Pneumococcal: 
23. Wissenschaftliche Begründung zur Aktualisierung der Empfehlung zur 
Indikationsimpfung gegen Pneumokokken für Kinder und Erwachsene; 
(www.rki.de/epidbull issue 37/2016)
24. Wissenschaftliche Begründung zur Aktualisierung der Pneumokokken-
Impfempfehlung bei Senioren (Standardimpfung ab 60 Jahren);  
(www.rki.de/epidbull issue 36/2016)
25. Wissenschaftliche Begründung zur Änderung der Pneumokokken-Impf-
empfehlung für Säuglinge (www.rki.de/epidbull issue 36/2015)
26. Wissenschaftliche Begründung für die Änderung der Empfehlung zur 
Indikationsimpfung gegen Pneumokokken  
(www.rki.de/epidbull issue 36/2014)
27. Begründungen zur allgemeinen Empfehlung der Impfung gegen Pneu-
mokokken im Säuglings- und Kindesalter – Pneumokokken-Impfung mit 
7-valentem Konjugatimpfstoff für Kinder unter 2 Jahren;  
(www.rki.de/epidbull issue 31/2006)
28. Zur Impfung gegen Pneumokokken-Krankheiten;  
(www.rki.de/epidbull issue 31/2005)
29. Begründung der STIKO-Empfehlung zur Pneumokokken-Impfung;  
(www.rki.de/epidbull issue 28/2001)
Rubella: 
30. Änderung der Empfehlungen zur Impfung gegen Röteln;  
(www.rki.de/epidbull issue 31/2010)
Rotavirus: 
31. Empfehlung und wissenschaftliche Begründung der Empfehlung zur 
Rotavirus-Standardimpfung von Säuglingen  
(www.rki.de/epidbull issue 35/2013)
Rabies: 
32. Änderung der Empfehlungen zur Impfung gegen Tollwut;  
(www.rki.de/epidbull issue 31/2010)
Varicella: 
33. Wissenschaftliche Begründung für die Änderung der Empfehlung zur pas-
siven Immunisierung mit Varizella-Zoster-Immunglobulin (VZIG); (www.
rki.de/epidbull Ausgabe 35/2015)
34. Impfung gegen Varizellen im Kindesalter: Empfehlung einer zweiten 
Varizellenimpfung (www.rki.de/epidbull issue 32/2009)
35. Begründung der STIKO für eine allgemeine Varizellenimpfung;  
(www.rki.de/epidbull issue 49/2004)
7. List of STIKO recommendations and scientific background papers 
National immunisation schedule available in 20 languages: www.stiko.de/en
Disclaimer
This document is a translation of the original Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute 
(www.rki.de/stiko-empfehlungen) on behalf of the Robert Koch Institute as of 8/2016. The German text is authoritative, and no liability is assumed for 
any translation errors or for the translation’s correctness in case of subsequent revisions to the German original.
